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Abstract 
 
The immune system is increasingly recognized for its role in the genesis and progression 
of hypertension. Catecholamines function in the neuro-hormonal regulation of blood 
pressure and have a well-established link to hypertension. It was hypothesized that cytokine 
signalling within the adrenal medulla influences catecholamine biosynthesis, thereby 
potentially impacting blood pressure. This study reports that IFN-α, IL-1β, IL-2, IL-6, IL-
10, TNF-α, and CCL2 affected transcript levels of tyrosine hydroxylase, dopamine β-
hydroxylase, and phenylethanolamine N-methyltransferase (PNMT) in PC12 cells. Further, 
simultaneous treatment with dexamethasone or forskolin produced context-dependent 
changes in the transcripts, some of which corresponded to alterations in PNMT promoter 
activation, but not to localization of glucocorticoid receptor. Thus, cytokines exert 
transcriptional control over catecholamine biosynthetic enzymes and cytokine signalling is 
integrated with hormonal and neural regulatory mechanisms in PC12 cells. Changes in 
adrenal cytokines during hypertension may promote blood pressure elevation by 
influencing catecholamine biosynthesis. 
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1 - Introduction 
1.1 - Hypertension and the Roles of Catecholamines and Inflammation 
1.1.1 - Hypertension 
 
Approximately one in five Canadian adults live with hypertension (Wilkins et al., 2010). 
Hypertension is defined as chronically elevated arterial blood pressure that is greater than 
or equal to 140 mm Hg mean systolic blood pressure (SBP) or 90 mm Hg mean diastolic 
blood pressure (DBP). Elevated blood pressure can cause changes in arterial structure that 
can increase risk of stroke, heart disease, kidney failure, and other diseases (World Health 
Organization, 2009). Hypertension is a leading cause of renal failure, second only to 
diabetes (Rosamond et al., 2008). Globally, high blood pressure is attributed to causing 
51% of stroke and 45% of coronary heart disease (World Health Organization, 2009). The 
significant health risks associated with hypertension have made it the world’s leading risk 
factor for death, estimated as the cause of 13.5% of premature deaths (Lawes et al., 2008). 
A majority of adults in both developing and developed countries have blood pressure that 
is higher than is optimal and the risk of dying from high blood pressure is particularly great 
in lower income countries (Wilkins et al., 2010; World Health Organization, 2009). 
Globally, the cost attributed to blood pressure above optimal levels, including both 
prehypertension and hypertension, is estimated at US$370 billion, roughly 10% of money 
spent on healthcare (Gaziano et al., 2009). Most recent estimates affirm that the treatment 
of hypertension is one of the most cost-effective approaches available for increasing 
quality-adjusted life-years and decreasing preventable deaths (Myers, 2007). 
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Hypertension can be classified into the categories of essential (or primary) and non-
essential (or secondary) hypertension. Hypertension is diagnosed as essential when there is 
no discernable underlying cause. Essential hypertension is often attributed to a combination 
of genetic and environmental factors. Non-essential hypertension is directly linked to a pre-
existing medical condition such as sleep apnea, kidney damage or diseases that consist of 
abnormal hormone production. Only a small minority (5-10%) of hypertension diagnoses 
are classified as non-essential, leaving the remaining majority (90-95%) of diagnosis to be 
classified as essential hypertension (Rimoldi et al., 2014).  
 
Like asthma, obesity, diabetes, and a multitude of other pathophysiological conditions, 
essential hypertension is a multigenic disease (see Fig. 1) that is highly influenced by 
environmental factors. Multigenic traits involve multiple genes and do not have a single 
recognizable pattern of inheritance as do single-locus Mendelian traits. Only a small 
proportion of cases of hypertension are directly caused by individual alleles which show 
distinct inheritance patterns within families. Most common genetic disorders arise as a 
complex interplay of intrinsic, extrinsic, and behavioral factors which together result in 
disease (O’Shaughnessy, 2001). Recent estimates of hypertension awareness and control 
have demonstrated increased proportions of people who are aware of their condition, who 
receive treatment, and who have controlled their blood pressure with medication (Wilkins 
et al., 2010). However, despite increased awareness and an abundance of available 
interventions, data from the 2007-2009 Canadian Health Measures Survey indicates that 
hypertension remains uncontrolled in 34% of Canadians (Wilkins et al., 2010). 
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Figure 1: Genetic complexity of blood pressure regulation. Hypertension is multigenic and can be caused by 
disturbances in multiple physiological systems. Above is an updated version of the 1960 Paige mosaic model 
of blood pressure regulation, adapted from Padmanabha et al., 2015. This model highlights some of the 
important factors identified from genetic studies, primarily from studies of monogenic forms of hypertension, 
and groups specific genes into broader physiological categories. 
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1.1.2 - Regulation of Blood Pressure 
 
Currently there is a panoply of treatments available for reducing blood pressure and 
combating hypertension. This is, in part, due to the numerous physiological parameters that 
influence blood pressure and that are accessible targets for treatment. Blood pressure is the 
product of cardiac output and total systemic vascular resistance. These variables are 
dependent on parameters such as blood volume, extracellular fluid volume, arterial and 
venous compliance, and resistance to venous return (see Fig. 2). Changes in the structure 
and function of kidneys, blood vessels, and the heart are regulated by neuroendocrine 
feedback mechanisms and serve to control blood volume and vascular resistance (Coffman, 
2011). Antihypertensive therapies must necessarily act upon the physiological mechanisms 
that control cardiac output and vascular resistance in order to effectively regulate blood 
pressure.  
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Figure 2: Schematic of the general mechanisms for blood pressure regulation. Arterial pressure is the product 
of cardiac output and systemic vascular resistance. This dynamic system is regulated by neural, hormonal, 
paracrine, and autocrine factors through changes in parameters such as vascular diameter, microvessel 
density, blood volume, etc. Control of fluid volume by the kidneys is an important means of regulating arterial 
pressure. Dashed lines depict negative feedback pathways important for the maintenance of homeostasis. For 
a comprehensive review, see Cowley (2006). RAAS = Renin-Angiotensin-Aldosterone System; NO = Nitric 
Oxide. 
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There are multiple drugs available for treating hypertension and they fall into 3 general 
categories: diuretics (including thiazides, loop diuretics, aldosterone blockers, and 
potassium sparers), adrenergic inhibitors (including peripheral inhibitors, β-blockers, 
central α2-agonists, α1-blockers, and combined α- β- blockers), and vasodilators (including 
direct vasodilators, angiotensin-converting enzyme [ACE] inhibitors, calcium channel 
blockers, and angiotensin [Ang] II receptor blockers) (Kaplan et al., 2010). Further, recent 
efforts have been made to develop surgical interventions for treating hypertension when 
other approaches prove inadequate. These include renal sympathetic denervation and the 
implantation of devices which electrically stimulate activation of the carotid baroreflex 
(Krum et al., 2014; Lohmeier & Iliescu, 2011). Changes in lifestyle, when possible, are also 
effective measures for treating hypertension and are recommended in current treatment 
guidelines by expert committees (Hypertension Canada, 2015; James et al., 2014; Krause 
et al., 2011; Mancia et al., 2013). Some of these lifestyle changes include the consumption 
of a healthy diet, engaging in regular physical activity, minimization of alcohol 
consumption, maintenance of healthy body weight (BMI 18.5-24.9 kg/m2), maintenance of 
a moderate waist circumference (<102 cm for men, <88 cm for women), moderate sodium 
intake (<2000 mg/day), and living in a smoke-free environment. Treatment 
recommendations for hypertension generally include a combination of antihypertensive 
drugs and appropriate lifestyle modifications, together with careful self-monitoring 
(Hypertension Canada, 2015). 
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1.1.3 - Hypertension and Catecholamine Biosynthesis  
 
Adrenergic inhibitors are among the most useful pharmacologic tools for treating 
hypertension. Adrenergic signalling via α- and β-adrenergic receptors can influence cardiac 
output and peripheral resistance. The catecholamines (CAs) dopamine (DA),  
norepinephrine (NE), and epinephrine (Epi) are involved in the regulation of the 
cardiovascular system. Because they are produced by neuroendocrine cells and have dual 
hormone and neurotransmitter functions, these CAs are classified both as neurotransmitters 
and/or neurohormones.  
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Figure 3: Catecholamine biosynthetic pathway. L-tyrosine is converted to L-DOPA by tyrosine hydroxylase, 
L-DOPA is converted to dopamine by aromatic amino acid decarboxylase, dopamine is converted to 
norepinephrine by dopamine β-hydroxylase, and norepinephrine is converted to epinephrine by 
phenylethanolamine N-methyltransferase. 
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The biosynthesis of CAs begins with the hydroxylation of tyrosine by the enzyme tyrosine 
hydroxylase (TH), producing L-3,4-dihydroxyphenylalanine (L-DOPA) (see Fig. 3) 
(Nagatsu et al., 1964). Next, L-DOPA is decarboxylated by the enzyme by L-aromatic 
amino acid decarboxylase (AADC), converting it to DA (Christenson et al., 1972). DA is 
then hydroxylated to produce NE; a reaction catalyzed by dopamine β-hydroxylase (DBH) 
(Weinshilboum & Axelrod, 1971). This sequence of reactions which converts tyrosine to 
NE is common in sympathetic and some brain neurons. In adrenal chromaffin cells one 
additional biosynthetic step occurs consisting of the methylation of NE by 
phenylethanolamine N-methyltransferase (PNMT) to produce Epi (Axelrod, 1962). Epi is 
the major secretory product of the adrenal gland, which is also the most abundant source of 
secreted Epi in the body (Hwang et al., 1994; Wong & Tank, 2007). Apart from being 
produced by the adrenal gland, DA and NE have important functions as neurotransmitters 
in the central and peripheral nervous systems. CAs in the adrenal medulla are sequestered 
in CA storage vesicles of chromaffin cells. When stimulated, chromaffin cells release CAs 
from their vesicles through Ca+2-mediated exocytosis (Douglas, 1968; Smith et al., 1973).  
 
Once released into circulation, CAs can interact with numerous adrenergic receptor types 
expressed in a variety of tissues. All CA receptors are G protein-coupled receptors (Caron 
& Lefkowitz, 1993). Adrenergic receptor subtypes include α1-, α2-, β1-, β2-, and β3- 
adrenergic receptors, some of which can be divided into further subtypes. Adrenergic 
receptors are activated by the CAs Epi and NE, with each receptor having a distinct affinity 
for each ligand. Like the adrenergic receptors, there are multiple forms of DA receptor, and 
they can be categorized in at least five (D1-5) different subtypes. Through these receptors, 
CAs can signal to numerous tissues throughout the body to produce a wide and coordinated 
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physiological response. The distribution and function of DA receptors suggests that DA 
may decrease BP by synergistically enhancing vasodilation, inhibiting synaptic NE release, 
decreasing circulating CAs, inhibiting aldosterone secretion and inhibiting sodium 
reabsorption in the kidney (Carey, 2001; Missale et al., 1998). β-adrenergic receptors are 
expressed in airway smooth muscle, epithelium, endothelium, immunocytes, and 
myocardium (Johnson, 2006). In cardiac tissue, although all three types are present, β1-
adrenergic receptors are the major β-adrenoceptor type expressed. β1- and β2-adrenoceptor-
mediated actions in the heart include positive inotropic (increased contractility), 
chronotropic (increased heart rate), dromotropic (increased conductivity), and 
bathmotropic (increased threshold of excitation) effects (Adameova et al., 2009). β3-
adrenoceptors require higher concentrations of CAs for activation than other β-
adrenoceptors, and β3-adenoceptor signalling is suggested to counteract effects of β1- and 
β2-adrenoceptor activation, thus mediating a protective feedback loop to prevent adrenergic 
overstimulation. The α-adrenoceptors are important for the maintenance of vascular tone 
as well as promoting smooth muscle contraction in other parts of the body. Sympathetic 
stimulation of α1-adrenoceptors is a major mechanism for sympathetic-mediated 
vasoconstriction (Guimarães & Moura, 2001). 
 
Studies have shown elevated plasma levels of Epi and NE in patients with essential 
hypertension as well as in animal models of hypertension (Axelrod, 1976; Borkowski & 
Quinn, 1984; Bühler et al., 1982; Goldstein, 1983; Jablonskis & Howe, 1994). CA 
production is dependent upon and correlated with the activity of the CA biosynthetic 
enzymes (Axelrod, 1976). Most studies have focused on three key CA-synthesizing 
enzymes: TH, DBH, and PNMT. Relative to TH, DBH, and PNMT, AADC activity is 
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typically high and is not rate limiting under normal physiological conditions (Berry et al., 
1996; Bowsher & Henry, 1986). In adrenal chromaffin cells, the expression of AADC is 
regulated to a lesser degree than the other CA biosynthetic enzymes (Kvetnansky et al., 
1971, 1970; Thoenen, 1972). Control of CA biosynthesis occurs primarily through the 
enzymes TH, DBH, and PNMT. Regulation of TH, DBH, and PNMT is achieved through 
both transcriptional and post-transcriptional mechanisms (Hwang & Joh, 1993; Tai & 
Wong, 2003; Tekin et al., 2014; Unsworth et al., 1999). Transcript levels of TH and PNMT, 
and activities of TH and DBH are enhanced in the adrenal medullas of genetically 
hypertensive rat models (Grobecker et al., 1982; Nagatsu et al., 1977; Nguyen et al., 2009; 
Reja et al., 2002). Further, PNMT is one of the putative gene loci linked to hypertension in 
genetic studies (Hoehe et al., 1992; Kaneda et al., 1988; Koike et al., 1995). Prolonged 
elevation of plasma CA levels can contribute to cardiac dysfunction by the over activation 
of vascular smooth muscle cells, resulting in ischemia and functional hypoxia; and 
oxidative damage (through the formation of oxidized CAs and oxygen free radicals), 
resulting in ultrastructural changes and cellular damage in cardiomyocytes (Adameova et 
al., 2009). Oxidative damage may also lead to immune activation that contributes to the 
further progression cardiovascular dysfunction (vide infra). Taken together, the molecular 
mechanisms that regulate the CA biosynthetic enzymes and their activities are of interest 
for the development of interventions for controlling blood pressure and preventing 
hypertension-associated disease. 
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1.1.4 - Hypertension and Inflammation 
 
The role of inflammation in the genesis of hypertension and accompanying organ damage 
is well established (Coffman, 2011). Inflammation is one of the most important factors 
contributing to cardiovascular risk; and it is a major part of the formation, progression and 
destabilization of atherosclerotic lesions (Hansson & Libby, 2006; Hollan et al., 2013; 
Libby, 2006). The link between immune and cardiovascular function is apparent in major 
immune diseases including rheumatic diseases, HIV, and psoriasis. Cardiovascular 
pathologies are the leading cause of premature mortality in patients with autoimmune 
rheumatic diseases (Zinger et al., 2009). Individuals with HIV infection have higher risk of 
cardiovascular disease (CVD), arterial stiffness, systolic and pulse pressures than matching 
uninfected individuals (Schillaci et al., 2013). A recent meta-analysis of observational 
studies concluded that psoriasis, a chronic inflammatory skin condition, is associated with 
increased prevalence and incidence of hypertension and that odds of hypertension increase 
with severity of psoriasis (Armstrong et al., 2013). Inflammation is an essential component 
of many diseases, and the connections between inflammation, hypertension, and CVD add 
support to its role in cardiovascular pathology. 
 
A prospective cohort study of 20,525 women concluded that high plasma levels of the 
inflammatory biomarker C-reactive protein are predictive for the development of 
hypertension (Sesso et al., 2003). Several studies have supported immune involvement in 
the elevated blood pressure of spontaneously hypertensive rats (SHR). Purcell and Gattone 
(1992) found that young SHR have an elevated rate of nerve growth into the thymus, a 
primary lymphoid organ important in T-cell development, compared to their normotensive 
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Wistar Kyoto counterparts. Others have found that treatment of SHR with antithymocyte 
serum or with the immunosuppressant cyclophosohamide lowers blood pressure (Bendich 
et al., 1981; Dzielak, 1991). Later studies established the role of the adaptive immune 
response in hypertension after finding that mice with a genetic deletion in recombinase-
activating protein (RAG-1 -/-), which lack T- and B-lymphocytes, experience blunted 
hypertension in response to both Ang II and deoxycorticosterone acetate (DOCA)-salt; 
adoptive transfer of T-cells restored the elevation in BP (Guzik et al., 2007). This study 
also identified the role of the cytokine TNF-α in BP elevation when mice treated with Ang 
II responded with both increased BP and increased production of TNF-α from T-cells; anti-
TNF-α therapy with etanercept (a TNF-α inhibitor) blunted Ang II-mediated elevations in 
BP (Guzik et al., 2007). Taken together, these studies suggest the potential for enhanced 
neural activation of T cells in hypertension as well as a functional importance of cytokine 
signalling in blood pressure regulation. Also supporting the role of cytokines in 
hypertension, multiple studies have identified altered profiles of pro- and anti-inflammatory 
cytokines and cytokine production capacity in humans when comparing hypertensive or 
prehypertensive patients to control subjects (Chrysohoou et al., 2004; Peeters et al., 2001; 
Stumpf et al., 2005, 2011). Although results are sometimes conflicting, these studies 
implicate cytokines such as IL-1, IL-6, IL-4, IL-7, IL-13, TNF-α, and CCL2 in human 
hypertension. Other cytokines not analyzed or not changed in circulating concentration may 
also be important in hypertension because of the potential for local regulatory effects at 
important centers for blood pressure regulation.  
 
Introduction of exogenous cytokine has been reported to induce changes in blood pressure. 
The cytokines IL-2 and IL-10 predominantly decrease blood pressure whereas the cytokine 
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IL-6 predominantly increases blood pressure. Other cytokines, such as TNF-α and IL-1, 
appear to have more intricate effects in relation to blood pressure regulation. In a screening 
experiment for changes in chemokine expression in DOCA/salt-induced hypertensive mice, 
transcript of the chemokine CCL2 and its receptor CCR2 were increased in aortas after the 
onset of hypertension. Treatment of mice with the CCR2 antagonist, INCB3344, 
substantially reduced DOCA/salt-induced infiltration of macrophages in aortic wall and 
DOCA/salt-induced elevations in blood pressure (Chan et al., 2012). Regulation of blood 
pressure by cytokines may be mediated by signalling to neural control centers or by direct 
actions on peripheral tissues. IL-1 can modulate blood pressure by influencing activity of 
neurohormonal control centers in the brain (McCann et al., 2000; Shi et al., 2010; 
Weidenfeld et al., 1989; Wilson et al., 1996). IL-1 can also modify vascular reactivity to 
NE (Baudry et al., 1996). Human cancer patients who receive high doses of IL-2 
demonstrate hemodynamic changes which suggest decreased peripheral resistance but 
increased cardiac output, with an overall reduction in mean arterial pressure (Gaynor et al., 
1988; Quan et al., 2005). Similar hemodynamic changes and hypotension are observed in 
experimental animals (Samlowski et al., 2003; Zeilender et al., 1989). Interestingly, IL-2 
can decrease circulating Epi in mice, and reversal of IL-2-induced hypotension is associated 
with a rise in circulating CAs (Samlowski et al., 2003). Like IL-2, experimentally-induced 
elevations in IL-10 levels are associated with decreases in blood pressure in animal models 
(Shi et al., 2010; Tinsley et al., 2010; Viel et al., 2010). IL-2 and other cytokines may reduce 
CA-mediated vasoconstriction by enhancing superoxide production, a molecule that can 
interact with CAs and inhibit their signalling function (Faggioni et al., 1994; Macarthur et 
al., 2000; Suzuki et al., 1990). In contrast to many other cytokines, IL-6 appears to increase 
blood pressure. In a large cohort study of healthy men, after controlling for age and other 
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cardiac risk factors, baseline plasma IL-6 levels were positively associated with increased 
SBP, DBP, pulse pressure, and mean arterial pressure (Chae et al., 2001). In animal 
experiments, IL-6 is shown to contribute to Ang II-induced, but not salt-sensitive 
hypertension (Brands et al., 2010; Lee et al., 2006; Schrader et al., 2007; Sturgis et al., 
2009). Pro-hypertensive effects of IL-6 may be mediated, in part, by vasoconstrictive 
effects of the cytokine that could result in increased peripheral resistance (Baudry et al., 
1996; Iversen et al., 1999). The major proinflammatory cytokine TNF-α can induce 
hypotension; however, inhibition of TNF with etanercept can prevent elevations in blood 
pressure caused by Ang II infusion, high-fructose feeding, and chronic inflammation in 
animal models (Feinberg et al., 1988; Guzik et al., 2007; Saks & Rosenblum, 1992; Tran 
et al., 2009; Venegas-Pont et al., 2010). TNF-α inhibition does not influence blood pressure 
in salt-dependent hypertension (Elmarakby et al., 2008). TNF-α can directly modulate 
arterial tone, and TNF-mediated signalling is involved in cardiac remodelling (Baudry et 
al., 1996; Iversen et al., 1999). Prenatal exposure to elevated levels of cytokines may also 
contribute to hypertension during adulthood (Samuelsson et al., 2006). This may involve 
morphological changes in tissues, as suggested by findings of increased innervation by 
adrenergic nerve fibers in human thymus after IFN-α therapy (Cavallotti et al., 2002). The 
blood pressure-regulatory effects of cytokines are complex, affecting multiple 
physiological systems in combination with hormones, neurotransmitters, and other 
signalling molecules. Future investigations into the integration of cytokine signalling with 
the other blood pressure regulatory systems will provide a better understanding of the 
events responsible for blood pressure dysregulation in disease.  
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Figure 4: Possible inflammatory processes contributing to the progression of hypertension. Dashed line 
illustrates the positive feedback loop that may lead to further elevations in blood pressure. 
  
 
17 
 
 
 
 
In describing a new model for how inflammation and hypertension interact, Harrison et al. 
(2011) hypothesized that modest elevations in BP (to values of SBP ~135-140 mm Hg), 
such as in prehypertension, largely caused by activity of the CNS, trigger immune changes 
that lead to hypertension (see Fig. 4). In this model, initial elevations in BP are responsible 
for neoantigen formation from oxidation and altered mechanical forces in vasculature. 
Neoantigens then induce inflammatory responses in the kidneys, blood vessels and other 
tissues, where lymphocyte infiltration and expression of inflammatory mediators such as 
CCL2, IL-1, IL-6, IL-17, and TNF-α is increased (Blasi et al., 2003; Crowley et al., 2008; 
Guzik et al., 2007; Madhur et al., 2010). These cytokines and inflammatory mediators work 
in concert with CAs and other BP-elevating hormones leading to vascular and renal 
dysfunction and initiating a more severe hypertensive state (Harrison et al., 2011). This 
feed-forward model described by Harrison et al. (2011) was foretelling of recent findings 
by Kirabo et al. (2014), whose work outlined a mechanism for hypertension based on an 
autoimmune-like reaction. In this mechanism, initial increases in BP lead to oxidative stress 
and lipid peroxidation which results in neoantigen formation, immune cell activation, and 
initiation of T-cell proliferation and cytokine production, leading to further increases in BP. 
With the support of these and other findings, a new paradigm is being established that 
implicates inflammation in the elevation of BP and progression of hypertension. 
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1.2 - The Major Mechanisms of Adrenal Medullary Regulation 
 
The adrenal gland is a key organ involved in the physiological adaptation to stress. The 
“fight-or-flight” response, first described by Cannon in the early 20th century, is 
characterized by increased blood pressure, increased heart rate, increased cardiac output, 
and changes in vascular and respiratory smooth muscle tone (Cannon & La Paz, 1911; 
Curtis & O’Keefe, 2002). The two major hormones secreted into circulation that facilitate 
the physiological stress response include cortisol and Epi, both being primarily products of 
the adrenal cortex and medulla respectively (Wong & Tank, 2007). There are two major 
effector circuits which are activated when the CNS perceives or anticipates a stress. They 
include the hypothalamic-pituitary-adrenal (HPA) axis, which stimulates the adrenal 
medulla through a hormonal mechanism, and the sympathetic-adrenal (SA) axis, which 
stimulates the adrenal medulla through a neural mechanism (Wong, 2006). These axes are 
in many ways physically distinct but they also have overlapping CNS components and 
physiological functions. Initiation of the physiological stress response, involving either 
HPA or SA axis, is primarily derived from structures of the limbic system. Termination of 
the stress response, caused by hormonal and neural feedback, also involves many of these 
same limbic structures. Integration of hormonal and neural signalling cascades allows the 
HPA and SA axis to function cooperatively while also tailoring individual responses to the 
specific initiating stimuli (Ulrich-Lai & Herman, 2009). 
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Figure 5: Hormonal and neural mechanisms regulating adrenal medullary chromaffin cells. The HPA-axis, 
comprised of the hormones corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), 
and cortisol, is shown in yellow. The SA-axis, comprised of afferent preganglionic sympathetic nervous 
system (SNS) fibers, is shown in blue. Green squares represent glucocorticoid (cortisol) produced in the 
adrenal cortex and traveling to the adrenal medulla through vasculature. Neurotransmitters, including 
acetylcholine and pituitary adenylate cyclase-activating peptide are released from synaptic terminals. Both 
glucocorticoids and sympathetic input stimulate release of catecholamines, primarily epinephrine, from 
chromaffin cells by exocytosis. Epinephrine then enters into systemic circulation and travels to target tissues 
throughout the body. 
  
 
20 
 
 
 
 
1.2.1 - Hypothalamic-Pituitary-Adrenal Axis 
 
The HPA axis consists of the paraventricular nucleus of the hypothalamus, the anterior 
pituitary gland and the adrenal gland (Smith & Vale, 2006). The HPA axis is activated 
when afferent neurons from multiple brain regions stimulate hypophysiotrophic neurons of 
the paraventricular nucleus and induce them to release corticotropin-releasing hormone 
(CRH) and vasopressin (Fig. 5). CRH and vasopressin then travel through hypophysial 
portal vessels to the anterior pituitary. CRH binds to receptors on pituitary corticotropes 
and promotes the secretion of adrenocorticotrophic hormone (ACTH) into systemic 
circulation. In the presence of CRH, vasopression has a synergistic effect, enhancing 
secretion of ACTH into circulation. ACTH then travels to parenchymal cells of the 
adrenocortical zona fasciculata, where it binds to plasma membrane receptors and initiates 
a rapid increase in the production and secretion of glucocorticoids (GCs). Once in systemic 
circulation, GCs bind to ubiquitously expressed intracellular glucocorticoid receptors 
(GRs) to induce physiological adaptations to the initial stressor. An intra-adrenal portal 
vascular system allows the exposure of adrenal medullary cells to especially high 
concentrations of GCs released from the adrenal cortex (Wurtman, 2002). GCs produce 
their cellular effects primarily by regulating transcription. Endogenous cortisol 
(corticosterone in rodents) is a lipid-soluble steroid hormone that binds to the cytoplasmic 
GR. Prior to ligand binding, GR is located in the cytoplasm as a multiprotein complex 
(Nicolaides et al., 2010). HSP90, one of the proteins in this complex, maintains the 
cytoplasmic retention of GR until binding of a ligand to GR causes dissociation from the 
complex and translocation into the nucleus. GR then homodimerizes and binds to 
glucocorticoid response elements (GRE) in the promoter regions of target genes directly, 
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or interacts with other transcription factor proteins causing transactivation or 
transrepression (Nicolaides et al., 2010). GCs are important regulators of homeostasis 
during basal conditions and during stress. They are critical for regulating cardiovascular, 
immune, metabolic, developmental, and reproductive processes (Smith & Vale, 2006). For 
example, the strong influence of GCs on immune function has allowed them to become 
some of the most commonly used compounds for therapeutic treatment of inflammatory, 
autoimmune, and lymphoproliferative disorders. In human leukocytes, approximately 20% 
of genes are regulated either positively or negatively by GCs (Galon et al., 2002). The 
effects of GCs on cardiovascular regulation are also important. Cortisol is a regulator of 
blood pressure in humans and can lead to hypertension when in excess (Kelly et al., 1998).  
 
One way that GCs can influence blood pressure is by influencing CA production. GCs 
directly increase the release of CAs by sympathetic nerves and adrenal medullary cells 
(Pilipović et al., 2012; Sharara-Chami et al., 2010). To compensate for increased secretion 
of CAs, GCs must increase CA production by regulating CA biosynthetic enzymes. Early 
evidence of GC control over adrenal CA biosynthesis was demonstrated in experiments 
performed by Wurtman and Axelrod (1965), who reported that ablation of the pituitary 
gland decreases PNMT activity, which can be restored by addition of ACTH or GC 
(Wurtman & Axelrod, 1965). Later, in vitro and in vivo experiments confirmed that GCs 
are responsible for increasing PNMT mRNA expression (Evinger et al., 1992; Sharara-
Chami et al., 2010; Wong et al., 1992), increasing the amount of functional intronless 
mRNA splice variant (Unsworth et al., 1999), increasing PNMT activity (Unsworth et al., 
1999), and enhancing PNMT protein stability via regulation of the co-substrate S-adenosyl-
methionine (Berenbeim et al., 1979; Wong et al., 1985, 1982) in adrenal chromaffin cells. 
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Studies in rat pheochromocytoma cells show that, in addition to PNMT, GCs regulate the 
other CA biosynthetic enzymes to produce parallel increases in their transcript level and 
activity (Kim et al., 1993b; Lewis et al., 1987, 1983; McMahon & Sabban, 1992; Tischler 
et al., 1983). Similar observations pertaining to regulation of enzyme transcript levels have 
also been made with primary cultures of bovine adrenal medullary cells; however, unlike 
rat pheochromocytoma cells, in bovine chromaffin cell primary cultures DBH transcript 
does not appear to be regulated by GC (Hwang & Joh, 1993; Stachowiak, Hong, et al., 
1990). 
 
Thus, GCs can increase transcript of TH, DBH, and PNMT. The site critical for GC 
responsiveness of the rat TH gene is located at about -5.7 kb and it closely resembles the 
activator protein 1 (AP-1) binding site (Rani et al., 2009). This finding is consistent with 
earlier observations the proximal promoter region (-773 to +27 bp) is not sufficient for GC 
regulation of the TH gene (Lewis et al., 1987, 1983). Another functional GRE has been 
identified at ~2.4 kb upstream in the mouse TH promoter (Hagerty et al., 2001). Several 
putative GREs have been identified in the first 1 kb of the upstream rat DBH gene, with 
corresponding sequences in the human DBH promoter (McMahon & Sabban, 1992). 
Although long exposure with GCs can increase transcript levels of DBH in PC12 cells, 
functionality of putative GREs in the DBH promoter has not yet been proven (McMahon 
& Sabban, 1992). In bovine chromaffin cells, GCs do not appear to regulate DBH 
transcription (Hwang & Joh, 1993). GCs are also important regulators of PNMT 
transcription (Wong et al., 1992). Three functional GREs have been identified in the 
proximal 1 kb rat PNMT promoter, and activation at these sites can be synergistically 
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regulated by the transcription factors early growth response 1 (Egr1) and activator protein 
2 (AP-2) (Ross et al., 1990; Tai et al., 2002; Wong et al., 1998). 
 
 
1.2.2 - Sympathetic-Adrenal Axis 
 
Working alongside the HPA-axis, another effector circuit that signals the adrenal medulla 
to synthesize and secrete Epi, the SA-axis, consists of the direct innervation of adrenal 
medullary chromaffin cells by the sympathetic nervous system (Axelrod & Reisine, 1984). 
Stress signals, primarily originating from limbic structures, are transmitted to preganglionic 
sympathetic neurons in the intermediolateral cell column of the thoracolumbar spinal cord 
which project, via the splanchnic nerve, to adrenal chromaffin cells of the adrenal medulla 
(Ulrich-Lai & Herman, 2009). The projections of preganglionic neurons from the 
splanchnic nerve terminate with synapses on adrenal medullary chromaffin cells. The 
neural stimulus is delivered to each chromaffin cell by several synaptic boutons and 
compelling evidence now suggests that gap junctions also help to propagate 
electrochemical signals between neighboring cells (Colomer et al., 2012; Desarménien et 
al., 2013). A combination of neurotransmitters and neuropeptides are released from 
sympathetic nerve terminals and bind to plasma membrane receptors on chromaffin cells. 
These substances stimulate the release large amounts of stored CAs from chromaffin cell 
vesicles via Ca+2-mediated exocytosis (Kvetnansky et al., 2009). Due to the direct 
innervations of adrenal chromaffin cells, the SA effector circuit has a short latency in 
comparison to excitation via the HPA axis, which is generally longer lasting and slower to 
respond (Droste et al., 2008). Stimulation of chromaffin cell activity by the SA axis may 
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contribute to hypertension through either an increase in sympathetic nerve firing or an 
unusually high sensitivity of chromaffin cells to sympathetic stimulation (Anderson et al., 
1989; Fhaner et al., 2013; Schlaich et al., 2004; Segura-Chama et al., 2015).  
 
Synaptic transmission at the SA synapse is mediated by the small molecule transmitter 
acetylcholine (ACh) and by neuroactive peptides. ACh is a transmitter for all preganglionic 
neurons of the autonomic nervous system and all postganglionic neurons of the 
parasympathetic nervous system (Kandel et al., 2012). The frequency of action potential 
firing at sympathetic nerve terminals influences the types of neurotransmitters released 
from the presynaptic nerve at the SA synapse. Stress is associated with high frequency 
splanchnic nerve firing, whereas basal sympathetic tone is characterized by lower 
frequency firing (Klevans & Gebber, 1970). In the preganglionic sympathetic nerves at the 
SA synapse, small synaptic vesicles (SSVs) contain ACh and large dense core vesicles 
(LDCVs) contain neuropeptides such as pituitary adenylate cyclase-activating peptide 
(PACAP). During high frequency firing both LDCVs and SSVs are released from the 
presynaptic nerve terminals. During basal conditions, only SSVs are released (Hökfelt et 
al., 2003). Both PACAP and ACh are integral at the SA synapse for promoting CA 
production and secretion (Wong, 2006). ACh is perhaps the best characterized molecule 
for synaptic transmission from the splanchnic nerve to the adrenal medulla. ACh binds to 
both nicotinic and muscarinic plasma membrane receptors on chromaffin cells. Cholinergic 
stimulation increases release of CAs from chromaffin cells (Evinger et al., 1994; 
Stachowiak, Hong, et al., 1990). Activation of nAChRs increases TH mRNA in chromaffin 
cells in a protein kinase A (PKA)-dependent manner (Gueorguiev et al., 1999; Hiremagalur 
et al., 1993; Stachowiak, Hong, et al., 1990). Cholinergic stimulation of chromaffin cells 
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also induces PNMT promoter-driven luciferase activity through a PKA-dependent 
mechanism (Wong et al., 2002). In vitro and in vivo evidence also supports the role of 
mAChRs in activating PNMT expression, via induction of the transcription factor Egr1 
(Morita et al., 1996; Morita & Wong, 1996).  
 
PACAP, primarily released from LDCVs during high frequency neuronal firing, is 
important for generating sustained increases in CA production by chromaffin cells 
(Wakade, 1988). PACAP is a ligand for the PAC1 receptor, which belongs to the subclass 
B1 GPCR. PAC1R signals through Gαs, which regulates adenylyl cyclase (Martin et al., 
2005). Binding of PACAP to PAC1 can signal through the conventional cyclic adenosine 
monophosphate (cAMP)-PKA pathway and at least two other insulated, cAMP-sensitive 
signalling pathways involving the signal transduction proteins exchange protein directly 
activated by cAMP (Epac) and the extracellular signal regulated kinases (ERK) 1 and 2 
(Emery & Eiden, 2012; Gerdin & Eiden, 2007; Kuri et al., 2009). The PAC1 receptor can 
also stimulate Gαq, which activates a phospholipase C (PLC)-protein kinase C (PKC) 
pathway (Yang et al., 2010). PACAP is capable of upregulating chromaffin cell expression 
of TH, DBH, and PNMT transcript (Stroth & Eiden, 2010; Tönshoff et al., 1997). 
 
As mentioned above, signalling via cAMP is an important molecular mechanism induced 
by both ACh and PACAP, and is involved in the regulation of CA biosynthetic enzymes in 
adrenal chromaffin cells. In primary cultured bovine adrenomedullary chromaffin cells, 
cAMP signalling produces synchronized increases in both transcript and activity levels of 
TH, DBH, and PNMT (Hwang et al., 1994). Similar activation of the CA biosynthetic 
enzymes by cAMP signalling occurs in rat chromaffin cells (Cheng et al., 2008; Lewis et 
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al., 1987, 1983; McMahon & Sabban, 1992; Wong et al., 2002). It should be noted that in 
both rat and bovine models, the induction of PNMT by cAMP is relatively small compared 
to the induction of TH and DBH. Signalling by cAMP activates PKA and can lead to tissue-
specific induction of other signalling pathways. For example, in PC12 cells, PACAP 
activates PKA signalling as well as signalling through the mitogen-activated protein 
kinases (MAPKs) p38 and ERK1/2 via a PKA dependent mechanism (Hansen et al., 2000; 
Vaudry et al., 2009). Signalling by ERK1/2, downstream of PKA activation, may contribute 
to PNMT transcriptional activation (Tai et al., 2010). The promoters of TH, DBH, and 
PNMT all contain motifs that can bind a number of common transcription factors. The 
transcription factors specificity protein 1 (Sp1), AP-2, and Egr1 all have functional 
consensus sequences in the promoters of TH, DBH, and PNMT rat genes. AP-1 and CRE 
motifs are also present within the rat TH and DBH promoters (Cheng et al., 2008; 
Kvetnansky et al., 2009). Induction of Egr1 in rat chromaffin cells occurs through a 
cAMP/PKA signalling mechanism (Ginty et al., 1991; Tai et al., 2001). In rat chromaffin 
cells, Egr1 regulates transcription of TH, DBH, and PNMT (Cheng et al., 2008; Ebert et 
al., 1994; Papanikolaou & Sabban, 2000). Splanchnic nerve activation, the cholinergic 
agonists nicotine and muscarine, and the neuropeptide PACAP are all inducers of Egr1 
(Morita et al., 1996; Wong et al., 2002). Transcriptional activation of TH and DBH also 
occurs through cAMP induction of transcription factor binding to AP-1 and CRE motifs 
(Kim et al., 1993a; Lim et al., 2000; Stachowiak, Goc, et al., 1990; Swanson et al., 1998). 
Other transcription factors potentially involved in the activation of CA biosynthetic 
enzymes by neural stimuli include Sp1 and AP-2 (Tai et al., 2010; Wong et al., 2002). 
Taken together, these studies suggest that the neuronal regulation of chromaffin cells 
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involves a number of transcription factors which can act individually or cooperatively to 
regulate expression of the enzymes responsible for CA biosynthesis.  
 
 
1.3 - Cytokine-Mediated Regulation of Catecholamine Biosynthesis 
 
Investigations into the potential role of cytokines in regulating CA production by the 
adrenal gland were, in part, inspired by insights gained from studying depression. 
Depression can be induced by alterations in NE and other neurotransmitter levels, and 
sympathetic hyperactivity is a well characterized component of the condition (Raison et al., 
2006). It has also been reported that a large proportion of patients receiving IFN-α therapy 
for treatment of cancer or infectious disease develop a behavioural syndrome that is very 
similar to major depression (Raison et al., 2006). This finding led to questions about the 
influence of cytokines on neurotransmitter production and the role of cytokines in 
regulating neural activity. Interestingly, depression is now associated both with elevations 
in plasma levels of proinflammatory cytokines and increased risk of hypertension, 
cardiovascular morbidity and mortality (Dowlati et al., 2010; Meng et al., 2012; Serrano et 
al., 2011). Although the causal relationships are not yet resolved, possible influences of 
inflammatory mediators such as cytokines on catecholaminergic cell function are now 
being investigated for their contribution to hypertension and CVD.  
 
In humans, treatment with IFN-α increases circulating levels of NE and Epi (Corssmit et 
al., 1996; Pende et al., 1990). Both intravenous and intracerebroventricular administration 
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of IL-1 to rats has been reported to increase plasma levels of NE and Epi, along with 
increased renal sympathetic nerve activity, SBP and heart rate (Kannan et al., 1996; Rivier 
et al., 1989). Central administration of IL-1 to rats has also been reported to increase ACTH 
secretion (Hashimoto et al., 1993). These findings suggest that IL-1 can activate HPA and 
SA axes by direct stimulation of regulatory centers within the brain. In humans, peripheral 
administration of IL-6 increases plasma cortisol and NE but does not affect plasma Epi 
levels (van Hall et al., 2003; Steensberg et al., 2003; Stouthard et al., 1995; Torpy et al., 
2000). Studies have suggested that peripherally, but not centrally administered, TNF-α 
elevates plasma CA levels in rats (Darling et al., 1989; De Laurentiis et al., 2002). Increased 
expression of IL-10 in the brain can inhibit elevations in plasma NE resulting from 
myocardial infarction in rats (Yu et al., 2007). Numerous cytokines, including IFNs, IL-1, 
IL-2, IL-6, and TNF-α induce changes in brain CA production or metabolism. Often, 
excitatory or inhibitory effects of cytokines in the brain are regionally dependent. Many of 
these same cytokines also modulate CA levels in the hypothalamus and influence function 
of the HPA axis (Dunn, 2006; Haddad et al., 2002). For example, central and peripheral 
administrations of IFN-α both alter levels of DA and NE in specific regions of the brain 
(Kamata et al., 2000; Kitagami et al., 2003; Kumai et al., 2000). The patterns of altered CA 
levels differ depending on the location, central or peripheral, of IFN-α administration. This 
suggests that direct and indirect sensing of cytokines by the brain induce unique responses 
in CA production by neural tissues. Numerous studies report similar regulatory effects for 
other cytokines in relation to brain cytokine production. In peripheral tissues, the effects of 
centrally or peripherally administered cytokines on CA levels and CA turnover is tissue-
specific, suggesting that cytokines can influence sympathetic activity both directly and 
indirectly, and that modulation of sympathetic nerve activity is specific rather than global 
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(Akiyoshi et al., 1990; Bognar et al., 1994; Hurst & Collins, 1993; Saito et al.; Sterin-Borda 
et al., 1996; Terao et al., 1994; Vriend et al., 1993). 
 
Cytokines have also been reported to regulate CA biosynthetic enzymes in vivo. In vivo 
studies using rats demonstrate that the cytokines IFN-α, IL-1β, and TNF-α regulate the CA 
biosynthetic enzyme TH in catecholaminergic cells of the brain and carotid body (Kang et 
al., 2009; Kumai et al., 2000; Sirivelu et al., 2012; Zhang et al., 2007). Interestingly, 
centrally administered cytokines can regulate CA biosynthetic enzymes in the adrenal 
medullas as well, likely through indirect mechanisms involving neural activation of level 
of the CNS and downstream effects mediated by the HPA or SA axes (Sim et al., 2012). 
For a more complete presentation of cytokine effects in the brain, HPA and SA axis, several 
reviews are available (Dunn, 2006; Elenkov et al., 2000; Haddad et al., 2002; Turnbull & 
Rivier, 1999). In sites of CA production outside the brain, the influence of cytokine 
signalling is only beginning to be understood.  
 
 
1.3.1 - Cytokine Expression by Adrenal Chromaffin Cells 
 
Adrenal cytokines can originate either systemically or locally; both situations have possible 
importance to cytokine-mediated regulation of adrenal function during hypertension. 
Numerous studies have identified unique profiles of circulating and tissue-expressed 
cytokines in hypertensive animal and human subjects (Chae et al., 2001; Chan et al., 2012; 
Chrysohoou et al., 2004; Shi et al., 2010). Even during normal physiological conditions, 
cytokines are expressed at detectable levels by adrenal medullary tissue. Cytokines are 
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expressed at varying levels throughout the adrenal gland (Call et al., 2000; González-
Hernández et al., 1996). The highest levels of expression are most commonly observed in 
the cortex or steroid-producing cells within the medulla, although expression of cytokines 
by chromaffin cells themselves has also been demonstrated in a number of studies (see 
Table 1). In humans, as in many species, the adrenal medulla is contiguous with the adrenal 
cortex, meaning that chromaffin cells are in direct contact with steroidogenic cells 
(Willenberg et al., 2002). Chromaffin cells are also receptive to many cytokines that are 
produced locally in the adrenal gland (see Table 1). Receptiveness to cytokines is 
demonstrated either by expression of cytokine receptors or by response of isolated 
chromaffin cells to cytokines. In instances where the cytokine and its receptor are co-
expressed, or when a locally produced cytokine can elicit a response in chromaffin cells, 
there is a possibility of autocrine or paracrine signalling that may influence endocrine 
function of the adrenal medulla (Douglas et al., 2010). 
 
  
 
31 
 
 
 
 
Table 1: Cytokine expression, responsiveness, and signalling observed in adrenal gland. JAK = Janus kinase; STAT = Signal Transducer and Activator of 
Transcription; NO = Nitric Oxide; GC = Guanylyl Cyclase; NPY = Neuropeptide Y; ZG = Zona Glomerulosa; ZF = Zona Fasciculata; ZR = Zona Reticularis. 
Cytokine Cytokine Expression (organism, tissue) Responsiveness (organism, tissue, mode of 
exposure) 
Cytokine Receptors 
(receptor name, 
organism, tissue) 
Supported Signalling 
Mechanisms 
 
 
IFN-α 
  
Bovine (medulla and chromaffin cells, in 
vitro) (Douglas & Bunn, 2009; Tachikawa et 
al., 1997; Toyohira et al., 1998) 
 
IFNAR2; Bovine 
(chromaffin cells) 
(Samal et al., 2013) 
 
PKC, ERK1/2, STAT 1 
and 2 (Douglas & Bunn, 
2009) 
PKC (Toyohira et al., 
1998) 
 
IL-1 α/β 
Human (cortex, medulla, and KAT45 
cells) (González-Hernández et al., 1995; 
Venihaki et al., 1998) 
Rat and Mouse (chromaffin cells) 
(Schultzberg et al., 1989) 
Rat (cortex and medulla, chromaffin, 
and PC12 cells) (Alheim et al., 1991; 
Andersson et al., 1992; Engström et al., 
2007; Nobel & Schultzberg, 1995; 
Schultzberg et al., 1995) 
Human (chromaffin and KAT45 cells, in 
vitro) (Rosmaninho-Salgado et al., 2009; 
Venihaki et al., 1998) 
Rat (medulla, in vivo) (Engström et al., 2007) 
Rat (adrenal and PC12 cells, in vitro) 
(Gwosdow, 1995; Gwosdow et al., 1992; 
Joseph et al., 1995; Li et al., 1994; Liu et al., 
2000; Venihaki et al., 1997) 
Mouse (primary chromaffin cells, in vitro) 
(Rosmaninho-Salgado et al., 2007) 
Bovine (medulla and chromaffin cells, in 
vitro) (Ait-Ali et al., 2004; Eskay & Eiden, 
1992; Morita et al., 2004; Yanagihara et al., 
1994) 
IL1R1; Rat (medulla and 
PC12 cells) (Engström 
et al., 2007; Shu et al., 
2007) 
IL1R2; Rat (medulla) 
(Liu et al., 2008) 
IL1RA; Rat (chromaffin 
cells) (Schultzberg et al., 
1995) 
 
MAPK, NO/PKC, 
NO/GC, NPY, PKA/NO 
(Rosmaninho-Salgado et 
al., 2009)  
NPY (Rosmaninho-
Salgado et al., 2007) 
ERK1/2 (Morita et al., 
2004) 
Ca2+ (Shu et al., 2007) 
PKA (Joseph et al., 
1995) 
CRH (Venihaki et al., 
1998) 
 
 
IL-6  
Human (cortex, medulla and chromaffin 
cells) (Kontogeorgos, Scheithauer, et al., 
2002; Kontogeorgos, Messini, et al., 
2002; Päth et al., 1997) 
Rat (medulla and PC12 cells) (Gadient 
et al., 1995; Liu et al., 2000; Möller et 
al., 2006; Sallmann et al., 2000) 
Bovine (ZG, ZF, ZR, medulla, and 
chromaffin cells) (Call et al., 2000; 
Samal et al., 2013) 
 
Human (adrenal, in vitro) (Päth et al., 1997; 
Willenberg et al., 2002) 
Rat (PC12, in vitro) (Li et al., 2012; Satoh et 
al., 1988) 
 
 
 
 
 
IL6R; Human (normal 
and macrophage-
depleted adrenal) (Päth 
et al., 1997; Willenberg 
et al., 2002), Rat 
(medulla) (Gadient et 
al., 1995) 
Gp130; Human 
(adrenal) (Willenberg et 
al., 2002), Rat (medulla) 
(Gadient et al., 1995) 
c-Fos (Satoh et al., 
1988) 
STAT3 (Li et al., 2012) 
 
  
 
32 
 
 
 
 
 
IL-10 
 
Rat (PC12) (Virmani et al., 2011) 
   
 
TNF-α 
Human (ZR, medulla, chromaffin cells, 
and pheochromocytoma) (González-
Hernández et al., 1996; Kontogeorgos, 
Scheithauer, et al., 2002; Tong et al., 
2004) 
Rat (PC12) (Liu et al., 2000) 
Bovine (adrenal capsule, cortex, and 
medulla) (Call et al., 2000)  
Rat (PC12, in vitro) (Goryo et al., 2011; Soeda 
et al., 2001; Trincavelli et al., 2003) 
Mouse (chromaffin cells, in vitro) (Ait-Ali, 
Stroth, et al., 2010) 
Bovine (chromaffin cells, in vitro) (Ait-Ali, 
Stroth, et al., 2010; Ait-Ali et al., 2004, 2008; 
Eskay & Eiden, 1992; Samal et al., 2013; 
Tamura et al., 2014; Xie et al., 1993) 
TNFR1; Bovine 
(chromaffin cells) 
(Tamura et al., 2014) 
TNFR2; Bovine 
(chromaffin cells) (Ait-
Ali et al., 2004, 2008; 
Tamura et al., 2014) 
ERK 1/2, p38, AP-1, 
NFκB (Ait-Ali et al., 
2004) 
NFκB (RelA, NFκB1, 
NFκB2) (Ait-Ali et al., 
2008) 
NFκB (various Rel class 
members) (Samal et al., 
2013) 
 
CCL2 
Rat (medulla, PC12_bPAC1hop cells) 
(Ait-Ali, Samal, et al., 2010; Liu et al., 
2008) 
Bovine (chromaffin cells) (Samal et al., 
2013) 
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1.3.2 - Cytokine Signalling in Chromaffin Cells 
 
Wherever they may originate, there is now strong evidence that cytokines profoundly 
influence the adrenal medulla by inducing changes in secretion, intracellular signalling, 
gene transcription, and translation (Bunn et al., 2012). The cytokines most studied for their 
influence on adrenal chromaffin cell function include IFN-α, IL-1β, IL-6, and TNF-α. 
These cytokines have likely received particular attention because they are prominent 
mediators of the systemic acute phase inflammatory response. 
 
IFN-α is a type I interferon and signals via the IFN-α receptor (IFNAR) complex, which 
includes IFNAR-1 and IFNAR-2 subunits. Transcript expression of IFNAR2 has been 
reported to increase in response to TNF-α treatment of bovine adrenal chromaffin cells 
(Samal et al., 2013). In many cells, binding of ligand to IFNAR induces activation of janus 
kinase (JAK)/signal transducer and activator of transcription (STAT) signalling, with the 
phosphorylation of STAT1 and STAT2, which dimerize to form two different 
transcriptional activator complexes (a STAT1 homodimer and STAT1-STAT2-IRF9 
heterotrimer). IFN-α can also activate other members of the STAT family (Caraglia et al., 
2005). Treatment of bovine chromaffin cells with IFN-α induces phosphorylation, 
increased expression, and nuclear translocation of STAT1 and STAT2 (Douglas & Bunn, 
2009). Further, IFN-α induces an increase in STAT3 phosphorylation but only increases 
nuclear STAT3 in a small proportion of cells (Douglas & Bunn, 2009). IFN-α also induces 
ERK1/2 signalling downstream of PKC activation in chromaffin cells (Douglas & Bunn, 
2009; Toyohira et al., 1998). Similar to IL-1, IFN-α inhibits ACh-stimulated CA secretion 
from chromaffin cells (Tachikawa et al., 1997). IFN-α also suppresses NE uptake by 
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cultured bovine chromaffin cells (Toyohira et al., 1998). IFN-α induces PKC- and ERK1/2-
dependent phosphorylation of TH at the serine (Ser) -31 site (no change in phosphorylation 
at Ser- 19 or 40), a post-translational modification that is linked to increased TH protein 
stability and activity (Douglas & Bunn, 2009; Moy & Tsai, 2004; Sutherland et al., 1993). 
ERK1/2 activation has also been reported to contribute to histamine and Ang II-induced 
increases in TH Ser 31 phosphorylation in bovine adrenal chromaffin cells (Bobrovskaya 
et al., 2001; Cammarota et al., 2003). Similar mechanisms of post-translational regulation 
of TH by ERK1/2 in adrenal chromaffin cells may be utilized by other ERK1/2-activating 
cytokines.  
 
IL-1β increases protein levels of the CA biosynthetic enzyme TH and, like IFN-α, induces 
phosphorylation of TH, in this case at the Ser-40 site which decreases inhibitory feedback 
of CAs on TH activity (Daubner et al., 1992; Rosmaninho-Salgado et al., 2009). Induction 
of TH phosphorylation by either IL-1β or IFN-α is transient (lasting <30 min) (Douglas & 
Bunn, 2009; Rosmaninho-Salgado et al., 2009). Long-term (24 hour) incubation with IL-
1β does increase total TH protein, while incubation with IFN-α has not yet been 
demonstrated to change TH protein level (Douglas & Bunn, 2009; Rosmaninho-Salgado et 
al., 2009). IL-1β-induced phosphorylation of TH at other Ser sites and the involvement of 
ERK1/2 signalling in IL-1β-induced TH regulation have not been investigated. IL-1 
receptor (IL-1R)1 and IL-1R2 are both expressed by rat adrenal medullary cells (Engström 
et al., 2007; Liu et al., 2008; Shu et al., 2007). IL-1R1 is responsible for transmembrane 
signalling and IL1R2 is a decoy receptor that acts as an endogenous inhibitor, like IL-1RA, 
to IL-1 signalling (Peters et al., 2013). IL-1 exists in two forms, IL-1α and IL-1β. Although 
they are structurally very different, both IL-1α and IL-1β bind to the IL-1Rs and the 
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neurochemical effects of both forms are very similar (Dunn, 2006). The similarity in effects 
of IL-1α and IL-1β is observed in adrenal chromaffin cells as well (Ait-Ali et al., 2004; 
Gwosdow, 1995; Joseph et al., 1995; Morita et al., 2004; Rosmaninho-Salgado et al., 2009). 
Stimulation of chromaffin cells with IL-1 can induce PKA, ERK1/2, nitric oxide 
(NO)/PKC, and NO/guanylyl cyclase intracellular signalling mechanisms (Joseph et al., 
1995; Morita et al., 2004; Rosmaninho-Salgado et al., 2009). Some IL-1-induced effects in 
chromaffin cells rely on intermediate autocrine signalling by factors such as NPY and CRH. 
IL-1 induction of NPY is responsible for downstream activation of PKA/NO, as well as 
ERK1/2, PKC and guanylyl cyclase pathways (Rosmaninho-Salgado et al., 2009). IL-1-
induced CRH expression can trigger a signalling loop, where CRH stimulates chromaffin 
cells to produce more IL-1β (Venihaki et al., 1997, 1998). Exposure to IL-1 can also cause 
increased expression of IL-1R1 in PC12 cells (Shu et al., 2007). An autocrine signalling 
loop utilizing IL-1 is supported in vivo. Intravenous injection of IL-1β has been reported to 
increase IL-1β and IL-1R1 mRNA levels in the medulla of rats (Engström et al., 2007).  
 
IL-1 alone has been reported to stimulate CA release from cultures of primary adrenal 
chromaffin cells and from pheochromocytomas (Gwosdow et al., 1992; Joseph et al., 1995; 
Rosmaninho-Salgado et al., 2009; Venihaki et al., 1998; Yanagihara et al., 1994). A 
significant portion of IL-1 induction of CA secretion relies on intermediate autocrine 
signalling by NPY (Rosmaninho-Salgado et al., 2009, 2007). In contrast to basal 
application of IL-1, when combined with ACh, IL-1 has an inhibitory effect on chromaffin 
cell CA release (Morita et al., 2004). IL-1 may function in the homeostatic control of CA 
production, where in the absence of stimulation by other sources, IL-1 enhances CA 
secretion, but when other activators are present IL-1 dampens their effects on CA secretion. 
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An auto-regulatory mechanism utilizing IL-1 is supported in vivo, as administration of 
cholinergic agonists increases IL-1 mRNA and decreases IL-1 protein stores in rat adrenals, 
suggesting enhanced IL-1 secretion in response to cholinergic stimulation (Andersson et 
al., 1992; Schultzberg et al., 1989). Interestingly, it has been reported that medullary 
expression of IL-R2 is increased by immobilization stress (Liu et al., 2008). If IL-1 is 
involved in homeostatic control of CA production, increased expression of the decoy 
receptor IL-1R2 may be a stress-specific response, whereby IL-1R2 prevents IL-1 from 
dampening CA release in response to a psychological stressor. Differential regulation of 
CA biosynthetic enzymes has been reported in response to long-term exposure to cold or 
immobilization stress (Kvetnansky, 2004; Kvetnansky et al., 2002, 2003). 
 
IL-6 binds to a receptor complex consisting of IL-6 receptor (IL-6R) and glycoprotein (gp) 
130 components. IL-6 binds to IL-6R, which can exist in either soluble or membrane-bound 
forms. The receptor-ligand complex then couples to the gp130 signal transducing 
component, promoting dimerization of gp130, facilitating downstream signalling 
(Kamimura et al., 2003). JAK/STAT3 and MAPK/ERK signalling are common IL-6 
activated pathways and are induced in neurons exposed to IL-6 (Fang et al., 2013). IL-6-
induced STAT3 signalling has been reported in PC12 cells, and both STAT3 and ERK1/2 
signalling mechanisms are supported by preliminary investigations using bovine 
chromaffin cells (Bunn et al., 2009; Li et al., 2012). The signal transducing component of 
the IL-6R complex is shared with other IL-6 family cytokines which, like IL-6, bind to 
ligand-specific receptors which then complex with a gp130. Thus, gp130 expression in the 
adrenal chromaffin cells can be inferred by responsiveness to other IL-6 family cytokines 
(Gadient et al., 1995). In immune cells, IL-6 activates AP-1 via a Ras-dependent MAPK 
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signalling mechanism (Jones et al., 2001). Activation of this transcription factor may also 
occur in chromaffin cells, as IL-6 has been reported to induce increases in c-fos transcript 
in PC12 cells (Satoh et al., 1988). In PC12 cells, high concentrations of IL-6 were also 
found to have an inhibitory effect the basal CA-producing function, decreasing DA and NE 
release as well as TH protein (Li et al., 2012).  
 
TNF-α binds to the plasma membrane situated receptors TNF receptor (TNFR) 1 and 
TNFR2. Binding of ligand to these receptors can initiate signalling cascades that utilize 
numerous protein kinases and lead to the activation of two major transcription factors, AP-
1 and NFκB (Baud & Karin, 2001). Bovine chromaffin cells have been found to express 
TNFR1 and TNFR2; however, TNFR1 appears to be more consistently expressed of the 
two (Ait-Ali et al., 2004, 2008; Tamura et al., 2014). A detailed investigation by Ait-Ali et 
al. (2004) found that TNF-α signalling in bovine chromaffin cells relies on ERK1/2 and 
p38 signal transduction mechanisms. Further, this study determined that activation of the 
transcription factor AP-1 occurs downstream of ERK1/2 activation, also finding that TNF-
α induces NFκB transcription factor activity in an ERK1/2-independent manner. In 
chromaffin cells, TNF-α-induced NFκB signalling appears to involve primarily the p65 
subunit, and possibly p52 and p50 subunits. Thus, transcriptional regulation likely occurs 
primarily via the p65 homodimer (Ait-Ali et al., 2008). The inhibitor of NFκB, PDTC, 
blocks the enhancement of the transcript levels of some genes by TNF-α (Ait-Ali et al., 
2008). Later experiments demonstrated that a variety of Rel family transcription factors are 
likely involved in the transcriptional regulatory effects of TNF-α (Samal et al., 2013). TNF-
α has been reported to induce and to modulate neuropeptide transcript and protein in bovine 
adrenal chromaffin cells (Ait-Ali, Stroth, et al., 2010; Ait-Ali et al., 2004; Eskay & Eiden, 
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1992). The effects of TNF-α on CA production have not been thoroughly investigated. A 
study of cytokine modulation of hypoxic response found that TNF-α can inhibit hypoxic 
induction of TH transcript (Goryo et al., 2011). An oligonucleotide microarray analysis of 
TNF-α-induced changes in bovine chromaffin cell transcriptome identified upregulation of 
PNMT transcript after long (48 hour), but not short (6 hour) exposures to the cytokine (Ait-
Ali et al., 2008). 
 
  
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Simplified schematic of neural, hormonal, and immune signalling pathways activated in adrenal chromaffin cells. These intracellular signals may be 
integrated to regulate production of CAs by chromaffin cells during normal or pathological conditions. Dashed line represents signalling mechanism supported by 
unpublished findings. ACh = Acetylcholine; PACAP = Pituitary Adenylate Cyclase-Activating Peptide; AC = Adenylyl Cyclase; GR = Glucocorticoid Receptor; 
HSP = Heat Shock Protein; NPY = Neuropeptide Y; PKA = Protein Kinase A; NO = Nitric Oxide; PKC = Protein Kinase C; GC = Guanylyl Cyclase.  
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In addition to direct signalling mechanisms of cytokines (Fig. 6), evidence is now emerging 
that cytokines can induce long-term changes in chromaffin cells through the activation of 
autocrine signalling loops. It is a well-established phenomenon that in immune cells 
cytokines favour their own production and the production of other cytokines, resulting in 
the formation of autocrine signalling cascades (Cavaillon et al., 2003). Two long 
established examples are IL-1 and TNF-α, which can stimulate their own production, along 
with the production of numerous other cytokines and inflammatory mediators (DeForge et 
al., 1992; Descoteaux & Matlashewski, 1990; Dinarello et al., 1987; Sparacio et al., 1992). 
These autocrine signalling loops can be self-regulating by stimulating the production of 
anti-inflammatory molecules such as IL-10 (de Waal Malefyt et al., 1993; Wanidworanun 
& Strober, 1993). By inducing the production of autocrine signalling molecules, cytokines 
may initiate long-term signalling programs in the adrenal medulla (Ait-Ali, Stroth, et al., 
2010; Call et al., 2000; Eskay & Eiden, 1992). For example, in primary cultures of bovine 
adrenal chromaffin cells, treatment with IL-1α has been reported to induce production of 
the cytokines IL-6 and TNF-α, as well as the neuropeptides VIP, NPY and Met-Enkephalin 
(Call et al., 2000; Eskay & Eiden, 1992). Intermediate autocrine signalling by NPY is 
critical for CA regulatory effects of IL-1 in chromaffin cells (Rosmaninho-Salgado et al., 
2009, 2007).  
 
Whether the responses of medullary cells to cytokines primarily functions for protective 
action against microbial challenge or if cytokines are a normal part of the diverse 
informational molecules that constantly regulate chromaffin cell homeostatic function, it is 
clear that local changes in cytokine signalling within the medulla has potential to exacerbate 
dysfunctional CA production. The regulation of adrenal function by cytokines and the 
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importance of changes in immune operation in contributing to the progression of 
hypertension and CVD are summarized above. The bi-directional relationship of the 
immune and neuro-endocrine systems conceivably provides fitness advantages to 
organisms in ways similar to the ‘neuro-immune circuit’ and may be a physiologically 
important part of maintaining health, dysfunction of which may result in pathology. The 
neuro-immune circuit has helped to explain perplexing phenomena such as the co-
morbidity of neuropsychiatric symptoms and inflammatory disease (Irwin & Cole, 2011). 
Similarly, integration of immune and adrenal functions provides an explanation for the 
aetiology of inflammation-related hypertension and may help to elucidate mechanisms of 
essential hypertension. 
 
 
1.3.3 - Cytokine Modulation of Glucocorticoid Signalling in Chromaffin Cells 
 
GCs and transmitters released at splanchnic-adrenal medullary synapses are important 
informational molecules which control Epi biosynthesis during normal and stress 
conditions [see (Wong, 2006) and references therein]. Chromaffin cells must coordinate 
intracellular signalling pathways induced by these and other informational molecules in 
order to produce appropriate responses under diverse physiological conditions. Cytokines 
produced either systemically or locally may be significant modulators of adrenal CA 
biosynthesis by altering chromaffin cell response to GCs and neurotransmitters. How, and 
to what extent, chromaffin cells simultaneously process information from immune and 
stress circuits is not well understood.  
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A number of the cytokines, including IFN-α, IL-1, IL-2, and TNF-α, have been reported to 
have inhibitory effects either on GC-induced GR nuclear translocation, GR-GRE binding, 
or GR-mediated gene transcription in diverse cell types (Pace & Miller, 2009; Smoak & 
Cidlowski, 2004). In mouse hippocampal HT22 cells, inhibition of GR transcriptional 
activity by IFN-α is dependent on JAK/STAT signalling pathway. STAT5 (not STAT1 or 
STAT2) appears to be the major mediator of IFN-α inhibitory effects on GR function in 
HT22 cells. Co-immunoprecipitation revealed that phosphorylated STAT5 binds to GR 
within the nucleus, and IFN-α-induced repression of GR function does not rely on 
inhibition of GR protein expression or nuclear translocation (Hu et al., 2009). In bovine 
chromaffin cells, IFN-α does not induce phosphorylation of STAT5; instead, IFN-α 
primarily activates STAT1 and STAT2 (Douglas & Bunn, 2009). A trimeric complex 
consisting of STAT1, STAT2, and interferon regulatory factor (IRF) 9, induced by IFN-
α/β receptor activation, is directly regulated by the nuclear coactivator of GR, 
glucocorticoid receptor-interacting protein (GRIP) 1 in murine macrophages (Flammer et 
al., 2010). Occupancy of target promoters by the STAT1-STAT2-IRF9 complex, pre-
initiation complex assembly, and type I IFN stimulated gene expression were reported to 
be repressed by dexamethasone (Dex)-induced depletion of GRIP. Inhibition of IFN-
induced gene expression by Dex appears to be caused by sequestration of GRIP1 from its 
functional activity as a coactivator for the STAT1-STAT2-IRF9 complex by GR. 
Conceivably, as long as GRIP1 protein levels are sufficiently low in adrenal chromaffin 
cells, this competitive mechanism could allow for the converse effect, whereby induction 
of the STAT1-STAT2-IRF9 complex by IFN-α leads to an inhibition of GR transcriptional 
effects through the repression of GRIP1 coactivation of GR.  
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In mouse fibroblast cells, inhibition of GR-GRE binding and GR-mediated promoter 
activation by IL-1 has been reported to depend on p38 signalling (Wang et al., 2004). The 
mechanism of p38 regulation of GR appears to involve direct phosphorylation of GR at the 
Ser-211 site (human) which modulates recruitment of GR coactivators to GRE-containing 
promoters (Kino et al., 2007; Miller et al., 2005). So far, p38 signalling has not been 
demonstrated as a significant contributor in IL-1 regulation of chromaffin cell function 
(Morita et al., 2004). Activation of p38 signalling pathway could possibly be a mechanism 
for inhibition of GR function by other cytokines, such as TNF-α, which have been reported 
to induce p38 signalling in chromaffin cells (Ait-Ali et al., 2004).  
 
IL-2 inhibition of GR is dependent on signal transduction by p38 (reported in murine HT-
2 T-helper cell line) and by JAK3 (reported in human PBMCs), both contributing to 
inhibition of GR nuclear translocation (Goleva et al., 2002; Irusen et al., 2002). In a murine 
T-lymphocyte cell line (CTLL-2) IL-2 represses GR transactivation through direct protein-
protein interactions of IL-2-induced STAT5 with GR following translocation to the nucleus 
(Biola et al., 2001).  
 
In human keratinocyte-derived HaCaT cells, TNF-α inhibits GC-induced transcriptional 
activation and GR nuclear translocation through a MEK-1/ERK-dependent mechanism 
(Onda et al., 2006). In human epithelial-derived HeLa cells, the inhibitory effect of MAPK 
signalling on GR function is demonstrated by inhibition of transcriptional activation of GR-
responsive luciferase constructs in the presence of constitutively activated p38 or JNK 
(Szatmáry et al., 2004). In human colon carcinoma-derived HCT116 cells, TNF-α can 
suppress GR transactivation by induction of FLICE-associated huge protein, which 
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competes with GR to bind the nuclear coactivator GRIP1 (Kino & Chrousos, 2003). 
Additionally, mutual repression of GR and NFκB function may result from transrepression 
(also known as tethering), caused by direct protein-protein interactions within the nucleus, 
or from competition for the cofactors CBP and steroid receptor coactivator-1 (Caldenhoven 
et al., 1995; Ray & Prefontaine, 1994; Sheppard et al., 1998).  
 
IL-6 enhances GR function through a STAT3-dependent mechanism in rat hepatoma H4IIE 
cells. Like STAT5, STAT3 forms complexes with GR in the nucleus; however, unlike 
STAT5, formation of a STAT3-GR complex appears to enhance promoter activation, both 
of IL-6 responsive elements and at GREs (Zhang et al., 1997). 
 
IL-10 is another cytokine reported to have synergistic rather than inhibitory effects on GR 
function. In a study using human leukocytes (U937 cells and whole blood cell cultures), 
treatment with the anti-inflammatory cytokine IL-10 had opposite effects to TNF-α. 
Inhibition of IL-6 secretion in whole-blood cell cultures and promotion of IL-1R antagonist 
secretion by human monocyte-derived U937 cells are two effects of Dex treatment. TNF-
α supresses, whereas IL-10 intensifies these Dex-induced activities (Franchimont et al., 
1999). The mechanism of IL-10 and GR signalling crosstalk is not yet understood; 
however, the effect may be achieved through an increase in GR production (Franchimont 
et al., 1999). Other possible mechanisms include IL-10-induced activation of STAT3, or 
IL-10 induced inhibition of NFκB, a transcription factor which inhibits GR function 
through transrepression (Ray & Prefontaine, 1994; Wang et al., 1995; Williams et al., 
2004). 
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The mechanisms of cytokine-induced GR regulation involve intermediate signalling 
molecules such as MAPKs and transcription factors including STAT1, STAT2, STAT3, 
STAT5, NFκB, and AP-1. In chromaffin cells, the most commonly reported signalling 
pathway by cytokines is that of the MAPK transduction molecules, particularly ERK1/2 
(Bunn et al., 2012). The MAPKs JNK and ERK can inhibit GR-mediated transcriptional 
activation by direct and indirect phosphorylation of GR at Ser-246 (rats, Ser-226 in 
humans), which may prevent signalling by promoting nuclear export of the transcription 
factor (Galliher-Beckley & Cidlowski, 2009; I Rogatsky et al., 1998). ERK1/2 signalling 
can also lead to AP-1 transcription factor activity. In chromaffin cells, both IL-6 and TNF-
α have been reported to induce activation of AP-1 subunits (Ait-Ali et al., 2004; Satoh et 
al., 1988). Treatment of bovine chromaffin cells with TNF-α increases transcriptional 
activation of AP-1 responsive promoter elements and increases binding of fos and jun 
proteins to TRE and CRE sequences through an ERK1/2-dependent mechanism (Ait-Ali et 
al., 2004). In humans, GC resistance is positively correlated with expression of c-fos in 
peripheral blood mononuclear cells in vivo (Takahashi et al., 2002). The interaction 
between GR and AP-1 is mutually repressive, involving tethering at the GR-DNA binding 
domain; thus, inhibition of GR function may occur after GR translocation to the nucleus 
(Heck et al., 1994; Kassel et al., 2004; Inez Rogatsky et al., 2002; Schüle et al., 1990). 
Activation of AP-1 signalling may be a component of chromaffin cell regulation by other 
ERK1/2-inducing cytokines, such as IFN-α and IL-1, and leading to insensitivity of 
chromaffin cells to GCs. 
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1.3.2 - Cytokine Modulation of Neurotransmitter and cAMP Signalling in Chromaffin 
Cells 
 
Integration of neurotransmitters such as ACh and PACAP with some cytokines has been 
demonstrated in chromaffin cells. IL-1 inhibits ACh-induced CA release via ERK1/2-
mediated suppression of Ca2+ influx in bovine chromaffin cells (Morita et al., 2004). 
Similarly, IFN-α has been reported to decrease ACh-stimulated CA secretion and Ca2+ 
influx in bovine chromaffin cells (Tachikawa et al., 1997). Chromaffin cell response to the 
neuropeptide PACAP is also modified by cytokine exposure. Combined treatment with 
PACAP and TNF-α synergistically upregulates VIP and galanin expression in bovine 
chromaffin cells (Ait-Ali, Stroth, et al., 2010).  
 
The signalling pathways of cAMP and cytokines may be integrated through interactions at 
MAPK, JAK-STAT, and NFκB. A number of studies report effects of cAMP/PKA 
signalling on the function of these other signalling molecules. In a human T-lymphocyte 
cell line (Jurkat cells) cAMP increase ERK1/2 activity by inhibiting function of 
haematopoietic protein tyrosine phosphatase, a negative regulator of ERK1/2 and p38 
(Saxena et al., 1999). In experiments using mouse (70Z/3) and human (Jurkat) lymphocyte 
cell lines, PKA was reported to contribute to the activation of NFκB by phosphorylating 
p65 following dissociation from IκB (Zhong et al., 1997). In human PBMCs, cAMP has an 
inhibitory effect on IL-6-induced STAT1 and STAT3 binding to DNA and prevents IL-6 
induction of an IL-6-responsive gene harbouring a STAT1 and STAT3 binding sequence 
(Sengupta et al., 1996). Compared to cAMP regulatory effects on cytokine signalling 
pathways, the effects of cytokines on cAMP signalling are less well understood. This may 
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in part be because cAMP activation occurs early in intracellular signalling cascades and the 
cellular output of cAMP activation is highly tissue-dependent (Taskén & Aandahl, 2004; 
Zhang et al., 2005). In chromaffin cells, transcription factors involved in response to 
cAMP/PKA signalling include Egr1, AP-1, and CREB (Ginty et al., 1991; Swanson et al., 
1998; Tai et al., 2001). Signalling via cAMP in chromaffin cells may also lead to activation 
of the MAPKs p38 and ERK1/2 (Hansen et al., 2000; Vaudry et al., 2009). In bovine 
chromaffin cells, the cytokines IL-1 and TNF-α have been reported to enhance induction 
of VIP and substance P expression by forskolin (Forsk) an activator of adenylyl cyclase 
(Eskay & Eiden, 1992). The mechanisms of cytokine modulation of cAMP signalling in 
chromaffin cells have not been defined. 
 
 
1.4 - Hypothesis and Objectives 
1.4.1 - Hypothesis  
 
Current literature supports roles for numerous cytokines in influencing blood pressure and 
in regulating function of adrenal chromaffin cells. Cytokines are expressed locally in the 
adrenal medulla and changes in circulating cytokine levels have been reported in 
hypertensive patient cohorts. It was predicted that cytokines can directly regulate the CA 
biosynthetic pathway in adrenal chromaffin cells, thus, providing a mechanism for 
inflammation-mediated regulation of CA production during hypertension. Based on the 
current literature, it was predicted that the cytokines IFN-α, IL-1β, TNF-α, and CCL2 
would increase, while IL-2, IL-6, and IL-10 would decrease CA biosynthetic enzyme 
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expression in PC12 cells. Further, it was hypothesized that cross-talk between immune and 
GC or cAMP signalling pathways would be observed in chromaffin cells. Changes in CA 
biosynthetic enzyme transcript levels were predicted to be regulated by changes in 
promoter activation. Cytokines were predicted to influence promoter activation by GCs, 
possibly by regulating nuclear localization of GR. 
  
 
1.4.2 - Objectives 
 
The objectives of this study were: (i) to analyze possible regulatory effects of cytokines on 
expression of the catecholamine biosynthetic enzymes TH, DBH and PNMT in PC12 cells.; 
(ii) to determine if hormonal or neural activation, mimicked by Dex and Forsk respectively, 
of TH, DBH and PNMT expression is modulated by cytokine signalling; and (iii) to 
investigate the mechanisms involved in the transcriptional regulatory effects of cytokines 
by analyzing PNMT promoter activation and GR nuclear localization.  
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2 - Methods 
2.1 - Cell Culture 
 
PC12 cells (ATCC; Manassas, Virginia, USA) were cultured in 100 mm tissue culture 
dishes (Biolite; Thermo Scientific; Waltham, Massachusetts, USA) in Dulbecco’s 
Modified Eagle’s Medium (DMEM), supplemented with 5% bovine calf serum, 5% equine 
serum (Hyclone Laboratories Inc.; Logan, Utah, USA) and 50 ng/ml gentamycin sulphate 
(Sigma-Aldrich; St. Louis, Missouri, USA). The cells were maintained in a humidified 
incubator at 37C containing 5% CO2 (Forma Series I Water Jacketed CO2 Incubator, 
Thermo Scientific) and grown to a confluence of 80-90% before being planted in a 
subsequent passage for experimentation. In all experiments, cells (passage 14-20) were 
grown in DMEM containing 5% charcoal-treated serum (equal parts bovine calf and equine 
serum) and gentamycin sulphate. Charcoal treatment was required for the removal of 
endogenous hormones and growth factors that would otherwise affect the expression of the 
genes of interest. In all experiments, prior to planting, cells were dissociated using trypsin, 
counted and viability determined using a cell viability analyzer (Vi-cell XR, Beckman 
Coulter; Mississauga, Ontario, Canada). In all experiments, cells were planted in 5% 
charcoal treated media (CTM) and allowed to acclimate for 24 hours to the reduced serum 
environment prior to treatment with cytokines. At the end of the acclimation period, 
medium was changed to fresh 5% CTM just prior to the addition of cytokines or drugs. 
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For RNA extraction and RT-qPCR experiments, 0.7 x10 6 cells were planted in 1 ml of 
medium per well in 12 well plates (Corning; Tewksbury, Massachusetts, USA). For 
luciferase assays, 0.35 x10 6 cells were planted in 1 ml per well in 24 well plates (Corning). 
For nuclear protein extraction and western blotting, 2.5 x10 6 cells were planted in 2 ml of 
medium per well in 6 well plates (Biolite dishes, Thermo Scientific). For microscopy, cells 
were planted using the same method as for nuclear protein extraction; however a coverslip 
was inserted into the bottom of the 6 well plates prior to planting cells.  
 
 
2.2 - Cell Treatments 
2.2.1 - Cytokine Sources, Preparation, and Application 
 
The cytokines used in the study were: rat IL-1β, rat IL-2, rat IL-6, rat IL-10, rat TNF-α 
(PeproTech Inc.; Rocky Hill, New Jersey, USA); rat IFN-α (Sigma-Aldrich) and rat CCL2 
(R&D systems; Minneapolis, Minnesota, USA). All cytokines were obtained as lyophilized 
powders and were resuspended in specific buffers prepared in 0.1% BSA (Table 2) as per 
manufacturer specifications, and further aliquoted for long term storage at -80°C.  
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Table 2: Buffer solutions used for resuspending cytokines and cytokine doses. 
     Cytokine Buffer Dose(s) Used 
IFN-α 20 mM Citric Acid and 150 mM NaCl, pH 5.0 1000 U/ml 
IL-1β 1 mM Sodium Acetate, pH 6.5 10 ng/ml and 50 ng/ml 
IL-2 1 mM Sodium Citrate, pH 4.0 100 ng/ml 
IL-6 1 mM Tris, pH 8.0 +0.01% SDS 10 ng/ml and 100 ng/ml 
IL-10 2 mM Sodium Phosphate, pH 7.0 50 ng/ml 
TNF-α 0.05x PBS, pH 7.1 100 ng/ml 
CCL2 No Additives (MilliQ H2O) 10 ng/ml and 100 ng/ml 
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Doses of cytokines and period of treatment were determined from prior screening 
experiments (data not shown) or were selected based on previously published literature (see 
Table 1 for papers). Two doses were selected for some cytokines when literature indicated 
multiple effective doses or bimodal response patterns (see Table 2). For the initial screening 
experiments, two time points (6 and 24 hours) of treatment with cytokine were used. All 
remaining experiments described below were performed with a 24-hour cytokine treatment. 
In all experimental designs, vehicle treated groups were included to account for effects 
from buffers. 
 
 
2.2.2 - Dexamethasone and Forskolin Sources, Preparation, and Application 
 
In all experiments analyzing the effect of cytokine on modifying responses to GC or cAMP 
signalling, samples were treated with Dex (Cayman Chemicals; Ann Arbor, Michigan, 
USA) or Forsk (L.C. Laboratories; Boston, Massachusetts, USA) respectively. Drugs were 
dissolved according to manufacturer’s instructions and stored at -80⁰C. Immediately prior 
to treating cells, drugs were diluted in 5% CTM to concentrations of 10 mM and 100 µM 
for Forsk and Dex respectively. Drugs were then applied to cells to obtain final 
concentrations of 10 µM and 1 µM for Forsk and Dex respectively. Cells were treated with 
either Dex of Forsk 6 hours prior to harvesting. Drug concentrations and treatment times 
were based on previous studies from our laboratory (Tai et al., 2002; Tai & Wong, 2003). 
 
 
 
  
 
53 
 
 
 
 
2.3 - RNA extraction, cDNA Synthesis and RT-qPCR 
2.3.1 - RNA Extraction 
 
At the end of treatment period, media was aspirated and RNA extracted with Trizol reagent 
(Sigma-Aldrich) as per the manufacturer’s protocol. In brief, cells were lysed with Trizol 
(500 µl) by pipetting several times before transferring to fresh tubes. Subsequently, 100 l 
of chloroform was added, mixed thoroughly by vortexing, and incubated for 10 minutes at 
room temperature, then the samples were centrifuged (12,000 x g) for 20 minutes at 4˚C. 
The aqueous phase containing the RNA was transferred to a fresh tube and RNA 
precipitated with isopropanol; 125 l of isopropanol was added per sample and incubated 
for 5-10 minutes, followed by centrifugation at 12,000 x g for 8 minutes at 4°C. The RNA 
pellet was washed with 500 l of 70% ethanol and centrifuged (7,500 x g) for 5 minutes at 
4˚C. Ethanol was then removed, RNA pellets air-dried, then dissolved in RNAse-free, 
diethyl pyrocarbonate-treated water. RNA concentration was determined at 260 nm using 
a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies; Wilmington, 
Delaware, USA). 
 
 
2.3.2 - DNAse Treatment and cDNA Synthesis 
 
Prior to cDNA synthesis, 2 µg of RNA was treated with Amplification Grade DNAse I (1 
U/μL; Sigma Aldrich) for 15 minutes at room temperature in the DNAse Reaction buffer. 
The reaction was terminated by the addition of a stop solution (50 mM EDTA; Sigma-
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Aldrich) followed by heating at 70°C for 10 minutes. For cDNA synthesis, M-MLV 
Reverse Transcriptase (M-MLV RT, Promega; Madison, Wisconsin, USA) was used as per 
the manufacturer’s instructions. Briefly, random primers (1 μg) were added to the DNAse-
treated RNA and heated for 5 minutes at 70°C. After cooling on ice, a master mix 
containing reaction buffer, dNTPs and M-MLV RT was added to the reaction mix and 
samples were reverse transcribed at 37°C for 1 hour using a Mini Thermal Cycler (BioRad). 
cDNAs were stored at -20⁰C for up to two weeks or -80⁰C for extended storage. 
 
 
2.3.3 - Quantitative Real Time PCR 
 
The transcripts for RPL29, TH, DBH, and PNMT were quantified by quantitative PCR 
using the GoTaq qPCR mastermix with SYBR Green (Promega) as per the instructions 
from the manufacturer. Briefly, for each gene, a standard curve using serial dilutions (0.78 
ng to 50 ng) of cDNA from control cells prepared in parallel with the experimental samples 
was used to determine the efficiency of PCR reactions and to validate primers. Following 
this, the lowest cDNA input that yielded high efficiency (95-100%) with Ct value between 
16-32 cycles was selected for subsequent qPCR analysis of target genes. The qPCRs were 
performed in a BioRad Chromo 4 machine and analyzed using the Opticon Monitor 
program (BioRad). The cycling conditions, primers, and cDNA input for each gene target 
is summarized Table 3. Specificity of the product was analyzed by assessing the melting 
curve. The Ct value for each sample was determined and fold changes were analyzed using 
the  
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𝑟𝑎𝑡𝑖𝑜 = (𝐸𝑡𝑎𝑟𝑔𝑒𝑡)
𝛥𝐶𝑇𝑡𝑎𝑟𝑔𝑒𝑡(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
(𝐸𝑟𝑒𝑓)
𝛥𝐶𝑇𝑟𝑒𝑓(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
⁄  method (Pfaffl, 
2001). For each experimental condition in a set, three biological replicates were included. 
All samples were run in duplicate in the qPCR (technical replicates), and the experiment 
was performed for n=3 unless otherwise stated in the legend.  
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Table 3: Primer specification and polymerase chain reaction set-up. 
Gene target Primer Sequences 
(5'-3') 
Amplicon 
Size (bp) 
Amplification Conditions cDNA 
Input 
(ng/µl) 
Primer 
Input 
(nM) 
 
PNMT 
X75333 
 
 
F: CATCGAGGAC 
AAGGGAGAGTC 
 
R: GCAGCGTCGT 
GATATGATAC 
 
219 
1. 95°C, 2 min 
2. 95°C, 1 min 
3. 60°C, 1 min 
4. 72°C, 1 min 
5. Plate read 
6. Go to line 2, 39 more 
times 
7. Melting Curve from 55-
95⁰C, read every 1°C, hold 
10 sec 
 
 
1 
 
 
300 
 
TH 
L22651 
 
 
F: GCGACAGAGTC 
TCATCGAGGAT 
 
R: AGAGCAGGTT 
GAGAACAGCATT 
 
 
150 
1. 95°C, 2 min 
2. 95°C, 1 min 
3. 58°C, 1 min 
4. 72°C, 1 min 
5. Plate read 
6. Go to line 2, 29 more 
times 
7. Melting Curve from 55-
95⁰C, read every 1°C, hold 
10 sec 
 
 
0.5 
 
 
600 
 
DBH 
NM_013158 
 
 
F: TTCCCCATGTT 
CAACGGACC 
 
R: GCTGTGTAGTG 
TAGACGGATGC 
 
240 
1. 95°C, 2 min 
2. 95°C, 1 min 
3. 58°C, 1 min 
4. 72°C, 1 min 
5. Plate read 
6. Go to line 2, 29 more 
times 
7. Melting Curve from 55-
95⁰C, read every 1°C, hold 
10 sec 
 
 
0.5 
 
 
600 
 
Beta Actin 
NM_031144 
 
 
F: TCTGTGTGGAT 
TGGTGGCTCT 
 
R: GACTCATCGTA 
CTCCTGCTTG 
 
83 
1. 95°C, 2 min 
2. 95°C, 1 min 
3. 58°C, 1 min 
4. 72°C, 1 min 
5. Plate read 
6. Go to line 2, 29 more 
times 
7. Melting Curve from 55-
95⁰C, read every 1°C, hold 
10 sec 
 
 
0.5 
 
 
600 
 
RPL29 
NM_017150 
 
F: CAGAAATGGC 
ATCAAGAAACCC 
 
R: TCTTGTTGTGC 
TTCTTGGCAAA 
 
105 
1. 95°C, 2 min 
2. 95°C, 1 min 
3. 58°C, 1 min 
4. 72°C, 1 min 
5. Plate read 
6. Go to line 2, 29 more 
times 
7. Melting Curve from 55-
95⁰C, read every 1°C, hold 
10 sec 
 
 
0.5 
 
 
600 
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2.5 - Western Blot 
2.5.1 - Protein Extraction and Quantification 
 
After completion of experimental treatments, samples were washed twice with cold PBS, 
scraped from the dish and transferred into a 1.5 ml tube in 1 ml of PBS. Next, samples were 
centrifuged (15,700 x g) for 10 seconds at 4 ºC and the supernatant discarded. The cells 
were resuspended with 150 l of lysis buffer A (10 mM Hepes-KOH, 1.5 mM MgCl2, 10 
mM KCl, 0.5 mM DTT, 0.2 mM PMSF, 20 µl protease inhibitor cocktail) and incubated 
on ice for 10 min. To enhance cell lysis, each sample was force ejected 10 times through a 
22-gauge needle using 1ml syringes. Next, samples were vortexed for 10 seconds, 
centrifuged (15,700 x g) for 10 seconds at 4 ºC, and the supernatant containing the cytosolic 
protein fraction was collected. For nuclear protein extraction, the pellet was resuspended 
in 50 l of lysis buffer C (20 mM Hepes KOH, 1.5 mM MgCl2, 420 mM NaCl, 25% 
glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 20 µl protease inhibitor cocktail) 
and incubated on ice for 20 min. Finally, samples were centrifuged (15,700 x g) for 2 
minutes at 4C and the supernatant containing nuclear proteins was collected into a new 
1.5 ml microcentrifuge tube. The samples were kept at -80°C for long-term storage.  
 
Protein concentration was determined using the Bradford assay employing a protein 
standard made with purified IgG ranging from 1-20 μg. The standards and sample dilutions 
were plated in a total volume of 20 μl in a clear 96 well flat-bottomed microplate (Corning). 
Next, 250 μl of 1x Bradford reagent (BioRad) was added to each well and incubated on a 
microplate shaker at room temperature for 5 minutes. The absorbance was measured at a 
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wavelength of 595 using a spectrophotometer (Bio-Tek Instruments Inc.; Winooski, 
Vermont, USA). The data was analyzed with KC-4 software to determine total amount of 
protein using the standard curve.  
 
 
2.5.2 - Sample Preparation 
 
From each sample, 30 g of total nuclear protein was transferred to a fresh tube, and their 
volume adjusted using lysis buffer C so that all samples have identical volumes of at least 
20 l (to facilitate accurate pipetting). Sample loading dye with β-mercaptoethanol was 
added and sample preparations were heated to 100C for 5 minutes and then immediately 
loaded onto gels.  
 
 
2.5.3 - Gel Casting 
 
Polyacrylamide gels for protein gel electrophoresis were prepared using 10% 
polyacrylamide resolving gel and 4% polyacrylamide stacking gel in 1.5 mm spaced plates 
(BioRad) and 15-well combs (BioRad). 10 l of PageRuler Prestained protein ladder 
(FroggaBio; North York, Ontario, Canada) was loaded as a molecular weight marker. Gels 
were run at 75 V until the dye front migrated from the stacking gel into the resolving gel. 
The voltage was then increased to 100 V and resolved until the dye front migrated to the 
base of the gel. 
  
 
59 
 
 
 
 
2.5.4 - Protein Transfer  
 
Gels were transferred onto 0.2 μm pore size nitrocellulose membranes (Pall Laboratories; 
Port Washington, New York, USA) using transfer cassettes and the immersed tank system 
(BioRad) with 1x Transfer buffer (250mM Tris, 1.92M glycine with 20% methanol) for 
1hr at 100 V.  
 
 
2.5.4 - Western Blot 
 
The membranes were incubated in blocking buffer made with 5% skim milk in Tris Buffer 
Saline with Tween (TBS-T; 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween-20) for 
a minimum of 30 minutes on a rocker. Membranes were then rinsed 4 times in TBS-T for 
10 minutes each at room temperature. The blots were incubated with primary antibody 
diluted in blocking buffer overnight at 4C on a rocker (1:1000 anti GR; clone M-20, Santa 
Cruz Biotechnology; Dallas, Texas, USA). Next, membranes were washed 4 times in TBS-
T (10 min each), and then incubated in horseradish peroxidase (HRP) conjugated anti-rabbit 
secondary antibody diluted in blocking buffer (1:2000 goat anti rabbit-HRP, Santa Cruz 
Biotechnology) for 1 hour. Finally, the membranes were washed again in TBS-T (10 min, 
4 times) were blotted dry and proteins were detected by enhanced chemiluminescence 
(ECL) and visualized on film processed on a developer. After the films were developed, 
membranes were washed twice with TBS-T and stained with Ponceau S. Images of the 
  
 
60 
 
 
 
 
Ponceau S stained membrane were acquired using the BioRad Molecular FX Imager with 
the Sypro Ruby red module (BioRad). 
 
 
2.5.5 - Densitometry 
 
For densitometric analysis, the band intensities were quantified using Image J software. For 
quantification of variation in GR under the various experimental conditions, the intensity 
of GR was normalized to the intensity of a band visualised by Ponceau S staining.  
 
 
2.4 - Analysis of PNMT Promoter Activation  
2.4.1 - Transformation and Plasmid Preparation 
 
PC12 cells were transfected with a PNMT promoter driven luciferase reporter construct 
(pGL893PNMT), consisting of the 893 bp proximal region of the rat PNMT promoter 
sequence (-863 to +18 bp) cloned into the pGL3Basic vector (Promega) (for details see Her 
et al., 1999). 1 µg of the stock plasmid was used to transform competent DH5α bacteria as 
per the manufacturer’s protocol (Invitrogen; Carlsbad, California, USA). Bacteria 
harbouring the plasmid were selected on Luria Bertani (LB) agar plates supplemented with 
ampicillin; selected colonies were then grown in LB broth with ampicillin and plasmid 
extracted using the PureLink HiPure Plasmid Filter MaxiPrep kit (Invitrogen). The plasmid 
was resuspended in Tris-EDTA (TE) buffer, DNA concentration determined by NanoDrop 
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ND-1000 Spectrophotometer (Nanodrop Technologies) and adjusted to a concentration of 
1 μg/μl before being aliquoted for storage at 4 ºC. 
 
 
2.4.2 - Transfection and Luciferase Assay 
 
PC12 cells were seeded in 24 well plates at a density of 0.35 x10 6 cells per well as described 
above. After the 24 hour acclimation period which followed planting, the PNMT promoter-
luciferase reporter gene construct pGL3RP893 was transfected into the cells using 
Turbofect transfection reagent (Promega). Briefly, for each well to be transfected, 1 μg of 
plasmid DNA was mixed with 100 μl of basal serum free DMEM and 1 μl of Turbofect 
reagent. The mixture was vortexed and allowed to incubate for 20 minutes at room 
temperature before adding to the cells. For multiple wells, a master mix of transfection 
solution was prepared. Six hours post-transfection, the cells were treated with cytokines or 
vehicle as per the experimental design for a total of 24 hours. 18 hours post cytokine 
treatment, Dex (1 μM) was added to appropriate sample groups for the remaining 6 hours 
prior to harvesting.  
 
At the end of treatments, the cells were washed twice with cold PBS and lysed with 100 µl 
of cell lysis reagent supplemented with DTT before freezing at -80°C. The plates were 
thawed on ice and the lysate, transferred to a V-shaped 96 well plate (Corning). The lysates 
were then centrifuged at 1000 g for 10 min at 4°C, a fraction of the supernatant (40 µl) was 
transferred into a 96-well white microplate (Corning). The luciferase activity was measured 
by direct injection of 50 μl Luciferase assay buffer into the wells using the injection needle 
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and pump assembly of a microplate reader (FLUOstar OPTIMA; BMG Labtech; 
Ortenberg, Baden-Württemberg, Germany). The protein concentration was determined 
using a Bradford assay as described above. Finally, the luciferase activity for each 
experimental condition was expressed relative to protein concentration (Relative light units 
or RLU/μg protein). 
 
 
2.6 - Microscopy 
 
PC12s were seeded on coverslips in 6 well plates and treated with cytokine or Dex or a 
combination of the two as outlined above. At the end of the treatments, cells were washed 
with PBS, fixed with 3.7% p-formaldehyde, permeabilized with 0.2% Triton X100 and 
stained with anti-GR for 1 hour at 37°C (1:20 dilution, 50 µl per coverslip; Clone, M-20, 
Santa Cruz Biotechnology). The coverslips were rinsed twice with PBS and incubated with 
1:2000 Alexa 488 conjugated secondary and 1:1000 DAPI (Invitrogen) prepared in 1% 
BSA for 30 minutes in the dark at room temperature. The coverslips were washed twice 
with PBS and mounted on slides using PermaFluor Mountant (Thermo Scientific). The 
slides were visualized on a confocal microscope (Nikon TE2000, Nikon Instruments Inc.; 
Melville, New York, USA). A minimum of 10 fields and 50 cells were visualised. 
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2.7 - Data Analysis 
 
All data are presented as the mean ± SEM (n = 3-9). Statistical significance between control 
and experimental groups was determined by unpaired, two-tailed t-tests or one-way 
ANOVA followed by a Dunnett test for post hoc analyses. Statistical analysis was 
performed using GraphPad Prism 5.00. Results were considered statistically significant 
with values of p ≤ 0.05. 
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3 - Results 
3.1 - Effects of Cytokines on Expression of Catecholamine Biosynthetic 
Enzymes 
 
PC12 cells were treated for 6 or 24 hours with the cytokines IFN-α, IL-1β, IL-2, IL-6, IL-
10, TNF-α, or CCL2 and transcript levels of TH, DBH, and PNMT were measured using 
RT-qPCR in order to determine the effects of cytokines on basal expression of the CA 
biosynthetic enzymes in adrenal chromaffin cells. 
 
TH: Results from the RT-qPCR analysis of PC12 cells treated for 6 or 24 hours with IFN-
α, IL-1β, IL-2, IL-6, or TNF-α show specific changes in TH mRNA level. IFN-α (1000 
U/ml) decreased TH mRNA levels after either 6 hour (0.78-fold; p<0.05) of 24 hour (0.74-
fold; p<0.001) incubation period (Fig. 7-A). IL-1β (10 ng/ml for 6 hours) decreased TH 
mRNA (0.74-fold; p<0.05) (Fig. 7-B). IL-2 (100 ng/ml for 6 hours) decreased TH mRNA 
to 0.73-fold (p<0.05) (Fig. 7-C). IL-6 decreased TH mRNA with both 10 ng/ml (0.73-fold; 
p<0.01) and 100 ng/ml (0.81-fold; p<0.05) treatments after 24 hour exposure (Fig. 7-D). 6 
hour TNF-α treatment decreased TH expression to 0.69-fold (p<0.001) and 24 hour 
treatment decreased expression to 0.75-fold (p<0.001) (Fig. 7-F). Neither IL-10 nor CCL2 
significantly changed TH mRNA levels with any of the conditions tested (Fig. 7- E and G). 
TH was significantly responsive to 5 of the 7 cytokines tested, all producing decreases in 
mRNA levels relative to respective control group.  
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DBH: Results from the RT-qPCR analysis of PC12 cells treated for 24 hours with IL-6 or 
TNF-α show specific changes in DBH mRNA level. 24 hour treatment with IL-6 (100 
ng/ml) increased DBH expression to 1.20 fold (p<0.05) (Fig. 8-D). 24 hour treatment with 
TNF-α decreased DBH expression to 0.42-fold (p<0.001) (Fig. 8-F). The cytokines IFN-α, 
IL-1β, IL-2, IL-10, and CCL2 did not significantly modify DBH mRNA levels in any of 
the conditions tested. 
 
PNMT: Results from RT-qPCR analysis of PC12 cells showed no significant changes in 
PNMT mRNA levels following incubation with either IFN-α, IL-1β, IL-2, IL-6 IL-10, 
TNF-α or CCL2 with any of the conditions tested (Fig. 9). 
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Figure 7 (A-D): Cytokine regulation of basal tyrosine hydroxylase (TH) expression in PC12 cells. Cells were 
treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 (D), IL-
10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was extracted, cDNA synthesised 
and RT-qPCR performed for detecting TH expression. The experiment was repeated two to three times with 
each treatment condition made in triplicate. Fold changes were calculated using the ΔΔCt method described 
by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 expression of each sample; 
cytokine-treated groups were then compared to the buffer-treated control group. The fold changes of 
cytokine-treated groups relative to respective control group are represented graphically; error bars display 
mean ± SEM. Statistical significance between control and cytokine treatment was determined with either 
unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple comparison test. Significant 
differences between cytokine-treated and control group are denoted by *p<0.05 or ***p<0.001. 
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Figure 7 (E-G): Cytokine regulation of basal tyrosine hydroxylase (TH) expression in PC12 cells. Cells were 
treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 (D), IL-
10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was extracted, cDNA synthesised 
and RT-qPCR performed for detecting TH expression. The experiment was repeated two to three times with 
each treatment condition made in triplicate. Fold changes were calculated using the ΔΔCt method described 
by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 expression of each sample; 
cytokine-treated groups were then compared to the buffer-treated control group. The fold changes of 
cytokine-treated groups relative to respective control group are represented graphically; error bars display 
mean ± SEM. Statistical significance between control and cytokine treatment was determined with either 
unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple comparison test. Significant 
differences between cytokine-treated and control group are denoted by *p<0.05 or ***p<0.001. 
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Figure 8 (A-D): Cytokine regulation of basal dopamine β-hydroxylase (DBH) expression in PC12 cells. Cells 
were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 
(D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was extracted, cDNA 
synthesised and RT-qPCR performed for detecting DBH expression. The experiment was repeated two to 
three times with each treatment condition made in triplicate. Fold changes were calculated using the ΔΔCt 
method described by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 
expression of each sample; cytokine-treated groups were then compared to the buffer-treated control group. 
The fold changes of cytokine-treated groups relative to respective control group are represented graphically; 
error bars display mean ± SEM. Statistical significance between control and cytokine treatment was 
determined with either unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple 
comparison test. Significant differences between cytokine-treated and control group are denoted by 
***p<0.001. 
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Figure 8 (E-G): Cytokine regulation of basal dopamine β-hydroxylase (DBH) expression in PC12 cells. Cells 
were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 
(D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was extracted, cDNA 
synthesised and RT-qPCR performed for detecting DBH expression. The experiment was repeated two to 
three times with each treatment condition made in triplicate. Fold changes were calculated using the ΔΔCt 
method described by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 
expression of each sample; cytokine-treated groups were then compared to the buffer-treated control group. 
The fold changes of cytokine-treated groups relative to respective control group are represented graphically; 
error bars display mean ± SEM. Statistical significance between control and cytokine treatment was 
determined with either unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple 
comparison test. Significant differences between cytokine-treated and control group are denoted by 
***p<0.001. 
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Figure 9 (A-D): Cytokine regulation of basal phenylethanolamine N-methyltransferase (PNMT) expression 
in PC12 cells. Cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β 
(B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting PNMT expression. The experiment was 
repeated two to three times with each treatment condition made in triplicate. Fold changes were calculated 
using the ΔΔCt method described by Pfaffl (2001) for qPCR quantification and all genes were normalized to 
RPL29 expression of each sample; cytokine-treated groups were then compared to the buffer-treated control 
group. The fold changes of cytokine-treated groups relative to respective control group are represented 
graphically; error bars display mean ± SEM. Statistical significance between control and cytokine treatment 
was determined with either unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple 
comparison test. 
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Figure 9 (E-G): Cytokine regulation of basal phenylethanolamine N-methyltransferase (PNMT) expression 
in PC12 cells. Cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-1β 
(B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting PNMT expression. The experiment was 
repeated two to three times with each treatment condition made in triplicate. Fold changes were calculated 
using the ΔΔCt method described by Pfaffl (2001) for qPCR quantification and all genes were normalized to 
RPL29 expression of each sample; cytokine-treated groups were then compared to the buffer-treated control 
group. The fold changes of cytokine-treated groups relative to respective control group are represented 
graphically; error bars display mean ± SEM. Statistical significance between control and cytokine treatment 
was determined with either unpaired two-tailed t-test or one-way ANOVA followed by Dunnett's multiple 
comparison test. 
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3.2 - Cytokines as Modifiers of Hormonal and Neural Activation of 
Catecholamine Biosynthetic Enzyme Gene Expression 
 
To investigate modulatory effects of cytokines on hormonal or neural activation of 
chromaffin cells, PC12 cells were treated for 24 hours with a combination of cytokine (IFN-
α, IL-1β, IL-2, IL-6, IL-10, TNF-α, or CCL2) and either Dex or Forsk. Dex is a potent GR 
agonist and was used to simulate chromaffin cell activation by adrenal cortical GC. Forsk 
is commonly used to experimentally activate adenylyl cyclase and increase intracellular 
cAMP levels. cAMP is a major component of the signalling mechanisms activated by the 
splanchnic-adrenal neurotransmitters ACh and PACAP. Dex (1 μM) and Forsk (10 μM) 
treatments were performed 6 hours prior to harvesting. Regulation of chromaffin cell CA 
biosynthetic enzyme expression was observed using RT-qPCR to measure changes in TH, 
DBH, and PNMT mRNA levels. The patterns of TH, DBH, and PNMT expression in 
response to activation by cAMP or GC were consistent with previous reports (Kim et al., 
1993b; Lewis et al., 1983; McMahon & Sabban, 1992). 
 
TH: There were significant increases in TH transcript when cells were treated with either 
Dex alone (2.7 fold; p<0.001) or Forsk alone (1.7 fold; p<0.001) (Fig. 10-A-G). Only IFN-
α and TNF-α significantly changed TH mRNA levels when combined with drug treatments. 
IFN-α inhibited Forsk-induced elevation of TH transcript (0.77 fold; p<0.001) when 
compared to Forsk alone (Fig. 10-A). TNF-α combined with drug treatment decreased TH 
transcript when compared to either Dex (0.85; p<0.01) or Forsk (0.65; p<0.001) alone. The 
inhibitory effect of TNF-α on TH expression was proportionally similar in both drug-
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treated and basal conditions (~25%). The cytokines IL-1β, IL-2, IL-6, IL-10, and CCL2 did 
not significantly change TH mRNA levels with either Dex or Forsk treatments. 
 
DBH: Treatment of PC12 cells with Dex or Forsk resulted in increases in DBH transcript 
of 1.7 fold (p<0.001) and 4.3 fold (p<0.001) respectively, relative to untreated control (Fig 
11-A-G). The cytokines IL-6, TNF-α, and CCL2 significantly changed DBH mRNA levels 
when combined with drug treatments. IL-6 potentiated the response to Dex by increasing 
DBH mRNA to 1.33 fold (p<0.01), and the response to Forsk by increasing DBH mRNA 
to 1.22 fold (p<0.05) when compared to either drug alone (Fig. 11–D). TNF-α decreased 
DBH mRNA expression when combined with either Dex (to 0.24 fold; p<0.001) or Forsk 
(to 0.39 fold; p<0.01) relative to DBH expression with either drug alone (Fig. 11– F). CCL2 
had no effects on DBH transcript under either basal conditions or when combined with 
Dex; however, CCL2 significantly increased DBH transcript (to 1.16 fold; p<0.05) in 
Forsk-treated cells when compared to Forsk treatment alone (Fig. 11-G). The cytokines 
IFN-α, IL-1β, IL-2, and IL-10 did not significantly change DBH mRNA levels with either 
Dex or Forsk treatments. 
 
PNMT: Expression of PNMT was increased ~25 fold (p<0.001) following treatment with 
Dex, while Forsk did not significantly change PNMT expression compared to control 
samples (Fig. 12-A-G). Decreased Dex-induced expression of PNMT mRNA was observed 
with IFN-α (to 0.59 fold; p<0.05; Fig. 12-A), IL-6 (to 0.31 fold; p<0.001; Fig. 12-D) or 
TNF-α (to 0.51 fold; p<0.001; Fig. 12-F) treatment. IL-10 (Fig. 12-E) was the only cytokine 
observed to potentiate (to 1.35 fold, p<0.01) the Dex-mediated increase in PNMT transcript 
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when compared to Dex alone. The cytokines IL-1β, IL-2, and CCL2 did not significantly 
change PNMT mRNA levels with Dex treatments. 
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Figure 10 (A-D): Cytokine regulation of glucocorticoid or cAMP-activated tyrosine hydroxylase (TH) 
expression. PC12 cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-
1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). 
Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of incubation. RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting TH expression. Each treatment was 
performed in triplicate. Fold changes were calculated using the ΔΔCt method described by Pfaffl (2001) for 
qPCR quantification and all genes were normalized to RPL29 expression of each sample; cytokine-treated 
groups were then compared to the buffer-treated control group. The fold changes of cytokine-treated groups 
relative to respective control group are represented graphically; error bars display mean ± SEM. Statistical 
significance between control and cytokine treatment was determined with either unpaired two-tailed t-test. 
Significant differences between cytokine-treated and control group are denoted by **p<0.01 or ***p<0.001. 
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Figure 10 (E-G): Cytokine regulation of glucocorticoid or cAMP-activated tyrosine hydroxylase (TH) 
expression. PC12 cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-
1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). 
Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of incubation. RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting TH expression. Each treatment was 
performed in triplicate. Fold changes were calculated using the ΔΔCt method described by Pfaffl (2001) for 
qPCR quantification and all genes were normalized to RPL29 expression of each sample; cytokine-treated 
groups were then compared to the buffer-treated control group. The fold changes of cytokine-treated groups 
relative to respective control group are represented graphically; error bars display mean ± SEM. Statistical 
significance between control and cytokine treatment was determined with either unpaired two-tailed t-test. 
Significant differences between cytokine-treated and control group are denoted by **p<0.01 or ***p<0.001. 
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Figure 11 (A-D): Cytokine regulation of glucocorticoid or cAMP-activated dopamine β-hydroxylase (DBH) 
expression. PC12 cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-
1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). 
Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of incubation. RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting DBH expression. Each treatment was 
performed in triplicate. Fold changes were calculated using the ΔΔCt method described by Pfaffl (2001) for 
qPCR quantification and all genes were normalized to RPL29 expression of each sample; cytokine-treated 
groups were then compared to the buffer-treated control group. The fold changes of cytokine-treated groups 
relative to respective control group are represented graphically; error bars display mean ± SEM. Statistical 
significance between control and cytokine treatment was determined with either unpaired two-tailed t-test. 
Significant differences between cytokine-treated and control group are denoted by *p<0.05, **p<0.01, or 
***p<0.001. 
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Figure 11 (E-G): Cytokine regulation of glucocorticoid or cAMP-activated dopamine β-hydroxylase (DBH) 
expression. PC12 cells were treated with either cytokine suspension buffer (control) or with IFN-α (A), IL-
1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours (left) or 24 hours (right). 
Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of incubation. RNA was 
extracted, cDNA synthesised and RT-qPCR performed for detecting DBH expression. Each treatment was 
performed in triplicate. Fold changes were calculated using the ΔΔCt method described by Pfaffl (2001) for 
qPCR quantification and all genes were normalized to RPL29 expression of each sample; cytokine-treated 
groups were then compared to the buffer-treated control group. The fold changes of cytokine-treated groups 
relative to respective control group are represented graphically; error bars display mean ± SEM. Statistical 
significance between control and cytokine treatment was determined with either unpaired two-tailed t-test. 
Significant differences between cytokine-treated and control group are denoted by *p<0.05, **p<0.01, or 
***p<0.001. 
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Figure 12 (A-D): Cytokine regulation of glucocorticoid or cAMP-activated phenylethanolamine N-
methyltransferase (PNMT) expression. PC12 cells were treated with either cytokine suspension buffer 
(control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours 
(left) or 24 hours (right). Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of 
incubation. RNA was extracted, cDNA synthesised and RT-qPCR performed for detecting PNMT expression. 
Each treatment was performed in triplicate. Fold changes were calculated using the ΔΔCt method described 
by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 expression of each sample; 
cytokine-treated groups were then compared to the buffer-treated control group. The fold changes of 
cytokine-treated groups relative to respective control group are represented graphically; error bars display 
mean ± SEM. Statistical significance between control and cytokine treatment was determined with either 
unpaired two-tailed t-test. Significant differences between cytokine-treated and control group are denoted by 
*p<0.05, **p<0.01, or ***p<0.001. 
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Figure 12 (E-G): Cytokine regulation of glucocorticoid or cAMP-activated phenylethanolamine N-
methyltransferase (PNMT) expression. PC12 cells were treated with either cytokine suspension buffer 
(control) or with IFN-α (A), IL-1β (B), IL-2 (C), IL-6 (D), IL-10 (E), TNF-α (F) or CCL2 (G) for 6 hours 
(left) or 24 hours (right). Dexamethasone (1 μM) or forskolin (10 μM) were added during the last 6 hours of 
incubation. RNA was extracted, cDNA synthesised and RT-qPCR performed for detecting PNMT expression. 
Each treatment was performed in triplicate. Fold changes were calculated using the ΔΔCt method described 
by Pfaffl (2001) for qPCR quantification and all genes were normalized to RPL29 expression of each sample; 
cytokine-treated groups were then compared to the buffer-treated control group. The fold changes of 
cytokine-treated groups relative to respective control group are represented graphically; error bars display 
mean ± SEM. Statistical significance between control and cytokine treatment was determined with either 
unpaired two-tailed t-test. Significant differences between cytokine-treated and control group are denoted by 
*p<0.05, **p<0.01, or ***p<0.001. 
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3.3 - Effects of Cytokines on Glucocorticoid Activation of the PNMT 
Promoter 
 
Results from this study show that the cytokines IFN-α and TNF-α have strong regulatory 
effects on basal and Dex-induced PNMT promoter activation (Fig. 13). To determine if 
cytokine-induced regulation of PNMT transcript levels are caused by changes in 
transcription rate or by post-transcriptional effects, a PNMT promoter-driven luciferase 
vector was used to examine promoter activation. PC12 cells were transfected with the 
PNMT promoter-driven luciferase vector prior to treatment with cytokines for 24 hours, 
followed by Dex treatment in the last 6 hours. Identical Dex treatment conditions have 
previously been reported to increase rat PNMT promoter activation in chromaffin cells in 
vitro (Tai et al., 2002). As expected, treatment with Dex alone increased PNMT promoter 
activity (2.6-fold, p<0.001), determined from increased luminescence (Fig. 13 A-D). 
Further, as seen in Fig. 13-A and 13-D, basal PNMT promoter activation was decreased by 
IFN-α (to 0.68 fold; p<0.05) or TNF-α (to 0.46 fold; p<0.001) treatments. IFN-α and TNF-
α both decreased PNMT promoter activation with Dex, reducing expression to 0.54 fold 
(p<0.001) and 0.45 fold (p<0.001) respectively. IL-6 and IL-10 had no effect on PNMT 
promoter activation, either alone, or in combination with Dex (Fig. 13-B and 13-C).  
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Figure 13: Cytokine regulation of phenylethanolamine N-methyltransferase (PNMT) promoter activation. 
PC12 cells were transfected with pGL3-PNMT 893 luciferase vector prior to treatment with IFN-α (A), IL-6 
(B), IL-10 (C) or TNF-α (D) for 24 hours. Dex (1 μM) was added during the last 6 hours of incubation. 
Luciferase activity was calculated relative to protein expression and normalized to the untreated control (first 
bar). The fold changes of cytokine-treated groups relative to respective control group are represented 
graphically; error bars display mean ± SEM. Statistical significance between control and cytokine treatment 
was determined by unpaired two-tailed t-test. Significant differences between cytokine-treated and control 
group are denoted by (p<0.05, **p<0.01, or ***p<0.001. 
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3.4 - Effect of Cytokines on Localization of Glucocorticoid Receptor  
3.4.1 - Western Blot Analysis 
 
To further analyze the mechanism by which cytokines can inhibit PNMT promoter 
activation, the nuclear translocation of GR in PC12 cells upon treatment with Dex was 
investigated. GR is a major regulator of PNMT promoter activation; the PNMT promoter 
contains three functional GREs which can bind GR and enhance PNMT expression. 
Further, as discussed above, numerous cytokines have been reported to suppress GC 
signalling by influencing the nuclear localization of GR. Regulation of Dex-mediated 
PNMT promoter activation by IFN-α and TNF-α may be mediated by inhibition of GR 
nuclear translocation.  
 
PC12 cells were treated with cytokines for 24 hours and Dex was added in the last 6 hours 
of treatment. At the end of the treatment period cells were harvested and nuclear extracts 
prepared as described in Materials and Methods. Nuclear extracts were resolved using 
PAGE, and membranes developed by ECL to detect GR in the nuclear extracts.  
 
Treatment of PC12 cells with Dex results in a 2.1 fold average increase in nuclear GR 
compared to untreated control (Fig. 14-A-D). The amount of nuclear GR protein did not 
change when cells were treated with IFN-α, IL-6, IL-10, or TNF-α in either the Dex-treated 
or the untreated groups. This suggests that none of the cytokines tested regulate PNMT 
promoter activation by influencing GR nuclear translocation in the experimental conditions 
tested. 
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Figure 14: Analyses of glucocorticoid receptor in presence of cytokines by western immunoblotting. PC12 
cells were treated with IFN-α (A), IL-6 (B), IL-10 (C) or TNF-α (D) or respective suspension buffers for 24 
hours. Dex (1 μM) was added during the last 6 hours of incubation. Nuclear extracts were collected as outlined 
in Materials and Methods, resolved by PAGE, and GR detected by ECL. The experiment was performed two 
times in triplicates. Bottom panels show representative gel images for each cytokine treatment. Densitometric 
analysis of the GR band was done using Image J software. GR expression was normalized to the density of a 
random band detected by Ponceau S staining of the membrane. The graph in the upper panel depicts fold 
changes relative to untreated control (first bar). Error bars show mean ± SEM. Statistical analysis was 
performed using unpaired two-way t test. 
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3.4.2 - Microscopy  
 
Observation of GR nuclear translocation by Western analyses revealed that IFN-α and 
TNF-α did not inhibit GR nuclear translocation. Fluorescence microscopy was used to 
visualize changes in cytoplasmic and nuclear GR. The experimental design was the same 
as for the western analyses with the exception that cells were grown on coverslips. At the 
end of the treatment period, cells were fixed, permeabilized and stained with an antibody 
against GR and with DAPI to visualize the nucleus. 
 
As expected, when compared to untreated controls, cells treated with Dex showed markedly 
higher nuclear localization of GR (green channel) (Fig. 15-A). Cytokine treatment with 
IFN-α, IL-6, IL-10 or TNF-α alone had no effect on the localization of GR as compared to 
untreated cells (green channel in upper panels of Fig. 15-A-E). Further, in cells treated with 
cytokine and Dex, there was no difference evident in the localization of GR when compared 
to Dex treatment alone (green channel in lower panels of Fig. 15-A-E). Taken together, 
these findings are in agreement with the observations made from the Western blotting 
experiments, suggesting that none of the cytokines tested influence localization of GR 
under the experimental conditions tested. 
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Figure 15 (A-B): Effect of cytokines on glucocorticoid receptor localization visualized by 
immunofluorescent microscopy. Representative untreated and Dex-treated (1 μM) controls (A) show 
enhanced nuclear translocation following incubation with Dex. PC12 cells were treated with IFN-α (B), IL-6 
(C), IL-10 (D) or TNF-α (E) for 24 hours, with or without Dex treatment during the last 6 hours of incubation. 
Cells were fixed, permeabilized and stained with anti-GR followed by secondary antibody conjugated with 
Alexa Flour 488 (green channel; left column in a panel). Nuclei were revealed with DAPI staining (blue 
channel; middle column in a panel). 
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Figure 15 (C-D): Effect of cytokines on glucocorticoid receptor localization visualized by 
immunofluorescent microscopy. Representative untreated and Dex-treated (1 μM) controls (A) show 
enhanced nuclear translocation following incubation with Dex. PC12 cells were treated with IFN-α (B), IL-6 
(C), IL-10 (D) or TNF-α (E) for 24 hours, with or without Dex treatment during the last 6 hours of incubation. 
Cells were fixed, permeabilized and stained with anti-GR followed by secondary antibody conjugated with 
Alexa Flour 488 (green channel; left column in a panel). Nuclei were revealed with DAPI staining (blue 
channel; middle column in a panel). 
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Figure 15 (E): Effect of cytokines on glucocorticoid receptor localization visualized by immunofluorescent 
microscopy. Representative untreated and Dex-treated (1 μM) controls (A) show enhanced nuclear 
translocation following incubation with Dex. PC12 cells were treated with IFN-α (B), IL-6 (C), IL-10 (D) or 
TNF-α (E) for 24 hours, with or without Dex treatment during the last 6 hours of incubation. Cells were fixed, 
permeabilized and stained with anti-GR followed by secondary antibody conjugated with Alexa Flour 488 
(green channel; left column in a panel). Nuclei were revealed with DAPI staining (blue channel; middle 
column in a panel). 
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4 - Discussion 
 
The present study provides compelling evidence that adrenal medullary chromaffin cells 
are capable of integrating signals from immune signalling molecules with those of the HPA 
and SA axes. These findings extend the current understanding of adrenal function in several 
important ways. This study supports, for the first time, adrenal chromaffin cell 
responsiveness to the cytokines IL-2, IL-10, and CCL2, and the potential regulatory effects 
of these cytokines on CA biosynthetic function. Moreover, robust inhibitory effects of IFN-
α or TNF-α on expression of TH transcript and on PNMT promoter activation were 
observed. This study also is the first to determine that chromaffin cells have the capacity to 
integrate cytokine and GC signalling, resulting in context-specific regulation of CA 
biosynthetic enzyme expression. This integration of cytokine and GC signalling occurs 
independently of GR nuclear translocation and may rely on specific inhibitory mechanisms 
within the nucleus.  
 
As shown in Table 1, many cytokines are constitutively expressed in the adrenal medulla, 
and can be derived locally from chromaffin cells themselves, from infiltrating immune 
cells, or from adjacent steroid-producing cells (Call et al., 2000; Engström et al., 2007; 
González-Hernández et al., 1994; Kontogeorgos, Messini, et al., 2002; Schober et al., 
1998). Based on the links between cytokines and hypertension, regulation of plasma CA 
levels, or direct effects on adrenal chromaffin cells, seven cytokines were selected to 
determine their influence on CA biosynthetic enzyme transcription. The concentrations of 
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cytokines used in our experiments were higher than concentrations reported in circulation 
during hypertension; however, local adrenal cytokine concentrations may differ greatly 
from those measured in circulation. Indeed, it has long been known that, compared to 
peripheral sources, locally derived signalling molecules are particularly potent regulators 
of adrenal chromaffin cell function (Wurtman, 1966). It was expected to that the cytokines 
IFN-α, IL-1β, TNF-α, and CCL2 would increase, while IL-2, IL-6, or IL-10 would decrease 
in CA biosynthetic enzyme expression in PC12 cells. 
 
Our experiments demonstrated that IFN-α decreases basal TH transcript level. Signalling 
by IFN-α in chromaffin cells may inhibit TH expression through activation of STAT1 and 
STAT2. IFN-α increases phosphorylation and nuclear translocation of STAT1 and STAT2 
in bovine chromaffin cells (Douglas & Bunn, 2009). STAT1 and STAT2 directly interact 
with the CREB-binding protein (CBP)/p300 family of transcriptional coactivators 
(Bhattacharya et al., 1996; Wojciak et al., 2009; Zhang et al., 1996). Competition of 
multiple transcription factors for CBP/p300 has been demonstrated as a mechanism for 
signal-induced transcriptional repression (Hottiger et al., 1998). CBP/p300 are also 
coactivators of CREB, a major mediator of CRE-dependent transcription of TH in PC12 
cells (Lewis-Tuffin et al., 2004; Vo & Goodman, 2001). The cAMP response element 
(CRE) at -45 in the proximal rat TH promoter is important for basal TH expression and 
cAMP response (Kim et al., 1993a; Trocmé et al., 1998). Preferential interaction of STAT1 
and/or STAT2 with CBP/p300 could potentially explain IFN-α-induced decreases in TH 
expression in basal conditions and in combination with Forsk. Like TH, the DBH promoter 
also contains CRE-like motifs. Two adjacent CRE-like motifs are located in the DB1 
element at approximately -180 bp in the DBH promoter; however, they appear to 
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preferentially bind Jun rather than CREB in the rat adrenal medulla (Sabban & Nankova, 
1998). This may be why IFN-α did not have the simultaneous effect of inhibiting DBH 
expression. Another change observed with IFN-α treatment was an inhibition of Dex-
induced PNMT mRNA expression. This finding was supported by a simultaneous reduction 
in PNMT promoter driven luciferase activity. The IFN-α-induced decreases in luciferase 
activity and PNMT mRNA with Dex treatment were proportionally similar, resulting in 
approximately 45% inhibition. Inhibition of Dex-induced PNMT promoter activation by 
IFN-α may be caused by transrepression of GR through STAT1 and STAT2 signalling. 
STAT1-STAT2-IRF9 complex may prevent GRIP1 coactivation of GR if concentrations 
of GRIP1 in chromaffin cells are limiting. Functional antagonism between STAT1-STAT2-
IRF9 complex and GR signalling has been reported previously in macrophages, which 
express GRIP1 protein at low levels (Flammer et al., 2010). IFN-α treatment also inhibited 
basal PNMT promoter expression in PC12 cells in absence of Dex, suggesting that the 
inhibition could also occur by an alternate mechanism, independent of direct interaction 
between IFN-α and GR signal transduction mechanisms. The inhibitory effects of IFN-α 
on CA biosynthetic enzyme expression were not expected. IFN-α has been reported to 
increase TH Ser-31 phosphorylation and inhibit NE uptake from chromaffin cells in vitro, 
suggesting that under basal conditions this cytokine promotes the production and release of 
CAs (Douglas & Bunn, 2009; Toyohira et al., 1998). Moreover, IFN-α treatment has been 
reported to increase circulating NE and Epi levels in humans (Corssmit et al., 1996; Pende 
et al., 1990). It is important to note, however, that IFN-α-induced TH Ser-31 
phosphorylation is transient (returning to baseline after 20 min), and long-term (48 hour) 
incubation with IFN-α does not increase TH protein levels in chromaffin cells (Douglas & 
Bunn, 2009). A study of patients receiving acute treatment with IFN-α reported enhanced 
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HPA axis response, with elevated plasma ACTH and cortisol (Capuron et al., 2003). 
Central or peripheral administration of IFN-α has also been reported to increase electrical 
activity of splenic sympathetic nerve filaments in rats (Katafuchi et al., 1991). Therefore, 
it is plausible that increases in circulating CA levels following injection of IFN-α in vivo 
result from indirect regulatory effects on adrenal CA production. Moreover, in line with 
our observation of IFN-α-induced inhibition of TH expression following Forsk treatment, 
IFN-α has been reported to inhibit ACh-stimulated CA secretion in bovine chromaffin cells 
(Tachikawa et al., 1997). 
 
IL-1β treatment decreased TH mRNA levels after short term (6 hour) incubation, but IL-
1β did not significantly alter expression of TH, DBH, or PNMT in any other conditions 
tested, including combined treatment with Dex or Forsk. IL-1β does not appear to be an 
important regulator of CA biosynthetic enzymes at the transcript level. IL-1β treatment has 
been reported to induce increases in total TH protein concentration (beginning at 6 hours), 
TH Ser-40 phosphorylation, and CA release from adrenal chromaffin cells (Gwosdow et 
al., 1992; Joseph et al., 1995; Rosmaninho-Salgado et al., 2009; Venihaki et al., 1998; 
Yanagihara et al., 1994). Conversely, IL-1α/β has been reported to inhibit ACh-induced 
CA release in bovine chromaffin cells (Morita et al., 2004). The increases in TH protein 
concentration in chromaffin cells reported in the literature may result from regulation of 
TH translation. In the absence of increases in TH transcript, induction of TH protein may 
occur either through an enhanced rate of TH translation or an increase in TH protein 
stability. Induction of TH protein and activity without concurrent elevation of TH mRNA 
has been reported in rodent midbrain dopaminergic neurons through a mechanism 
regulating TH mRNA translation rate (Chen et al., 2008).  
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After 6 hour incubation with IL-2, TH mRNA was decreased and after 24 hour incubation 
with IL-10 Dex-induced elevation in PNMT mRNA was increased. Regulatory effects of 
IL-2 were not observed in any other experimental condition tested. IL-10 did not 
significantly change basal or Dex-induced PNMT promoter activation. IL-2 and IL-10 have 
both been reported to decrease blood pressure and plasma Epi concentration. It was 
expected that these cytokines would decrease expression of the CA biosynthetic enzymes 
in adrenal chromaffin cells. Observations from the present study suggest that the 
suppressive effect of IL-10 on plasma Epi concentration result from indirect action of the 
cytokine on adrenal CA biosynthesis. IL-10 potentiation of PNMT transcriptional 
activation by Dex may rely on post-transcriptional mechanisms, whereby integration of IL-
10 and GC signalling pathways results in altered PNMT mRNA splicing or stability. The 
expression ratio of two distinct PNMT mRNA splice variants is subject to regulation and 
has been correlated with PNMT enzyme activity (Unsworth et al., 1999). IL-10 could 
plausibly increase the relative expression of the functional intronless PNMT transcript 
compared to the intron-retaining transcript without changing overall PNMT promoter 
activation. 
 
The present study demonstrates that treatment with IL-6 (beginning at 24 hours) decreases 
basal TH transcript in PC12 cells. Treatment of PC12 cells with IL-6 has previously been 
reported to decrease TH protein levels (beginning at 24 hours) as well as DA and NE release 
(Li et al., 2012). The IL-6-induced decrease in TH protein expression reported by Li et al. 
(2012) may thus result from regulatory effects at the level of gene expression which lead 
to reduced TH translation. Another possible mechanism may be gp-130-mediated 
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destabilization of TH protein, which has been reported in experiments using sympathetic 
neurons treated with the IL-6 family cytokines ciliary neurotrophic factor and leukemia 
inhibitory factor (Shi & Habecker, 2012). Increased expression of DBH with IL-6 treatment 
was also observed. This increased DBH expression was present in control, Dex-, and Forsk-
treated groups, suggesting that this effect is independent GC or cAMP signalling 
mechanisms. IL-6 signalling may cause repression of nuclear factors that bind to negative-
acting cis-regulatory elements in the DBH promoter (Kim et al., 1998; Shaskus et al., 1995). 
Another possibility is that IL-6 signalling may inhibit basal Egr1 function, which could 
conceivably result in reduced expression of TH and PNMT, and increased DBH expression, 
which is similar to the overall effects observed in the present experiments (Cheng et al., 
2008). Because TH functions at an earlier stage in CA biosynthesis than DBH, the 
inhibitory effects of IL-6 on TH expression may still limit activity of DBH, resulting in the 
reported IL-6-induced decreases in DA and NE release from chromaffin cells (Li et al., 
2012). IL-6 also had a pronounced inhibitory effect on Dex-induced elevation of PNMT 
transcript in PC12 cells. IL-6 did not produce a corresponding decrease in PNMT promoter 
activation, suggesting that the effects of IL-6 on PNMT mRNA expression rely on post-
transcriptional mechanisms. Induction of STAT3 signalling has been reported in PC12 cells 
treated with IL-6 (Li et al., 2012). STAT3 has also been reported to function synergistically 
with GR signalling in rat hepatoma H4IIE cells, forming complexes with GR in the nucleus 
and enhancing activation of IL-6 responsive elements and GREs (Zhang et al., 1997). Our 
data suggest that synergistic interaction of IL-6 signalling pathways and GR must be tissue-
specific, as the effect was not observed in PC12 cells. Potential synergistic interaction of 
GR and STAT3 may be inhibited by other IL-6-induced signalling events in chromaffin 
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cells, or IL-6 may fail to induce nuclear coactivators important in the function of the 
STAT3-GR complex.  
 
Incubation of PC12 cells with TNF-α produced significant changes in gene expression of 
all three CA biosynthetic enzymes analyzed. TNF-α significantly decreased mRNA levels 
of TH and DBH but did not decrease PNMT transcript level, although a decrease in PNMT 
promoter activation was observed in luciferase experiments. A previous study using 
oligonucleotide microarray analysis of TNF-α-induced changes in bovine chromaffin cell 
transcriptome identified upregulation of PNMT transcript after long (48 hour), but not short 
(6 hour) exposures to the cytokine (Ait-Ali et al., 2008). Preliminary experiments from the 
present study did not reveal similar increases in PNMT mRNA levels with 48 hour exposure 
to TNF-α; however, the concentration reported to increase PNMT was slightly higher than 
our maximum tested concentration of 100 ng/ml (data not shown). The difference in 
observations may be due to differences in the model systems used to assess cytokine 
regulation of chromaffin cells. Differences between transcriptomes of bovine chromaffin 
cells and PC12 cells following exposure to the same stimuli has been reported in the 
literature (Ait-Ali, Samal, et al., 2010). Our observations from luciferase assay suggest that 
TNF-α signalling in chromaffin cells does influence PNMT promoter activation, 
presumably affecting transcription factor interaction with cis-regulatory elements. TNF-α 
has been previously reported to have a suppressive effect on transactivation by the 
transcription factor Sp1. Experiments using mouse hepatic and adipose cells demonstrated 
that TNF-α signalling suppresses Sp1 binding to cis-regulatory elements and reduces 
activity of an Sp1-responsive promoter-driven luciferase construct (Barth et al., 2002; 
Denson et al., 2001). Promoters of TH, DBH, and PNMT all contain Sp1 binding sites. 
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Sp1binds to a cis-regulatory motif in the rat TH promoter that is critical for promoter 
activation (Yang et al., 1998). Sp1 has also been reported to bind to the DBH promoter, 
although its functional role is not fully understood (Kim et al., 1998; Seo et al., 1996). 
There are two functional Sp1 binding sites in the PNMT promoter and Sp1contributes to 
basal PNMT expression in chromaffin cells (Her et al., 1999, 2003). Taken together, TNF-
α-mediated inhibition of transactivation by Sp1 could explain the observed attenuation of 
CA biosynthetic enzyme expression. Because TNF-α-induced decreases in gene expression 
with Dex or Forsk were observed in tandem with decreases in basal expression, it is not 
clear if the reduction in gene expression with combined application of TNF-α and either 
Dex or Forsk is caused by functional interaction of the signalling pathways. TNF-α-
mediated inhibition of CA biosynthetic enzyme expression with Dex or Forsk may result 
from inhibition of a factor, such as Sp1, that is involved in constitutive PNMT expression. 
Such a mechanism for the repressive action of TNF-α on CA enzyme expression is 
supported by the observation that GR localization following Dex treatment was not 
significantly altered by TNF-α. Contradictory to the present observations, it was expected 
that TNF-α would promote expression of the CA biosynthetic enzymes. Circulating TNF-
α concentrations are elevated in both mild hypertension and essential hypertension patient 
cohorts relative their normotensive counterparts (Chrysohoou et al., 2004; Stumpf et al., 
2005). Further, it has been reported that peripherally administered TNF-α elevates plasma 
CA levels in rats (Darling et al., 1989). The expected potentiation of CA biosynthetic 
function in chromaffin cells by TNF-α was not observed, either under basal conditions or 
when combined with stimulators of GR or cAMP signalling. Elevation of circulating CAs 
by TNF-α may involve adrenal regulation through an intermediate mechanism similar to 
the HPA and sympathetic activation reported with IFN-α. The present study is the first 
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detailed investigation of the direct regulatory effects of TNF-α on the CA biosynthetic 
pathway in adrenal chromaffin cells. TNF-α has a marked inhibitory effect on CA 
biosynthetic enzyme expression. This cytokine has been reported to be constitutively 
expressed in the adrenal medulla (see Table 1). Thus, TNF-α may be an important local 
regulator of chromaffin cell CA biosynthetic function in vivo, perhaps functioning to 
decrease CA production during the progression of hypertension or other inflammatory 
pathologies. 
 
Though the chemotactic cytokine CCL2 may be a promising therapeutic target for reducing 
blood pressure in hypertension, it does not appear to be an important regulator of 
chromaffin cell CA biosynthetic enzyme expression. CCL2 has been suggested to 
contribute to the progression of hypertension, with CCR2 antagonist reducing DOCA/salt-
induced elevations in blood pressure in mice. Elevated CCL2 expression is also reported in 
mildly hypertensive humans and in tissues of hypertensive animals models, including 
mouse aorta and rat renal cortex (Blasi et al., 2003; Chan et al., 2012; Stumpf et al., 2005). 
This cytokine contributes to monocyte infiltration in the aortic wall in DOCA/salt 
hypertensive mice (Chan et al., 2012). CCL2 expression in the adrenal medulla may be 
increased in hypertension, originating either from the dense networks of medullary blood 
vessels or from the chromaffin cells themselves. Indeed, CCL2 transcript expression has 
been reported in bovine and rat chromaffin cells, with mRNA levels increasing in vitro 
following incubation with TNF-α (>10-fold; bovine chromaffin cells) or PACAP (3-fold; 
PC12_bPAC1hop cells), and in vivo in response to 2 hour immobilization stress (8-fold, rat 
medulla) (Ait-Ali, Samal, et al., 2010; Liu et al., 2008; Samal et al., 2013). Inflammation 
and enhanced SA activation may produce similar elevations in medullary CCL2 expression 
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during hypertension. Rather than directly influencing blood pressure through regulation of 
chromaffin cell CA biosynthetic function, the blood pressure regulatory effects of CCL2 
may be mediated by macrophage infiltration and the effects of macrophages on 
physiological mechanisms of blood pressure control. 
 
The cytokines IFN-α, IL-1, IL-2, IL-6, IL-10, TNF-α, and CCL2 can regulate expression 
of enzymes responsible for production of CAs, the major secretory product of chromaffin 
cells and important regulators of blood pressure homeostasis. The cytokines exerting the 
strongest regulatory effects included IFN-α, IL-6, and TNF-α, which exhibited 
predominantly inhibitory effects on CA biosynthetic enzyme expression. Constitutively 
expressed cytokines may have an important function in homeostatic control of CA 
biosynthesis by suppressing CA production during inflammation. This could be an 
important innate mechanism for preventing the progression of hypertension, by dampening 
CA production as inflammation increases with elevations in blood pressure. The inhibitory 
effect of cytokines on GC-induced activation of chromaffin cells may also be part of an 
autoregulatory loop to prevent medullary over-stimulation. This could be particularly 
important in inflammatory conditions where inflammation induces a compensatory 
increase GC secretion (an important endogenous anti-inflammatory molecule) (McEwen et 
al., 1997). Increased concentration of GCs in the adrenal medulla, in the absence of such 
an inhibitory mechanism, would result in increased CA release (Wurtman & Axelrod, 
1966). Thus, immune changes that coincide with hypertension could potentially help to 
signal an adaptive inhibition of CA biosynthetic function of the adrenal medulla. Cytokine-
mediated antagonism of GC-induced chromaffin cell activation could also help to prevent 
adrenal medullary over-activation in situations when inflammation leads to increased 
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secretion of anti-inflammatory GCs. Both effects may be protective mechanisms against 
the development of hypertension; disturbance of such mechanisms, either by changes in 
local adrenal cytokine levels or by disruption of chromaffin cell sensitivity to cytokines 
could be a contributing factor to the progression of hypertension in some individuals. 
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5 - Conclusion 
 
Findings from the present study suggest that: (i) cytokines including IFN-α, IL-1β, IL-2, 
IL-6, and TNF-α have direct regulatory effects on basal expression of the CA biosynthetic 
enzymes TH and DBH; (ii) adrenal chromaffin cells have the capacity to integrate signals 
from immune, hormonal, and neural origins to produce unique regulatory effects on CA 
biosynthetic machinery and that these effects are particularly prominent in the regulation 
of PNMT by IFN-α, IL-6, IL-10, and TNF-α; (iii) the regulatory effects of some cytokines, 
such as IFN-α and TNF-α, involve direct control of PNMT promoter activation, whereas 
other cytokines, such as IL-6 and IL-10, regulate PNMT transcript levels without affecting 
promoter activation; and, (iv) cytokines do not regulate promoter activation by influencing 
GR nuclear translocation in chromaffin cells. These findings support the possibility of a 
novel mechanism, whereby cytokines could function as potent endogenous regulators of 
CA biosynthetic function in the adrenal with the possibility of contributing to the 
progression of hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
101 
 
 
 
 
 
6 - Future Directions 
 
A potential role for multiple cytokines in regulating CA biosynthetic function of adrenal 
chromaffin cells has now been identified in vitro. It is unknown if medullary expression of 
cytokines that have robust regulatory effects on chromaffin cells, such as IFN-α, IL-6, or 
TNF-α, is changed during hypertension. Future investigations to determine changes in local 
cytokine concentrations in the adrenal medulla during prehypertension and overt 
hypertension will provide better insight into the relevance of cytokine-chromaffin cell 
signalling in this disease. The particular molecular mechanisms involved in integrating 
hormonal, neural, and immune inputs to the adrenal medulla also remain to be elucidated. 
The patterns of cytokine regulatory effects on CA enzyme expression provide insight into 
potential points of interaction. Because cytokines inhibited PNMT transcript in presence of 
Dex, and also altered promoter activation under these conditions, it would be interesting to 
elucidate if these effects could be mediated by changes in GR binding at GREs or by 
changes in other transcription factors that mediate PNMT transcription. Future 
investigations into converging immune, hormonal, and neural signalling mechanisms may 
also include: competition studies between STAT1/2 with CREB and GR for coactivators 
CBP/p300 and GRIP1 respectively, the influence of IL-6 on binding of negative acting cis-
regulatory elements in the DBH promoter, regulation of Egr1-mediated promoter activation 
by IL-6, suppression of Sp1 binding to cis-regulatory elements or Sp1-responsive 
promoter-driven luciferase activity by TNF-α. 
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Appendices 
Appendix A: Summary of significant results. Significant changes induced by cytokine treatments are 
expressed as ↑ for increase and ↓ for decrease relative to the applicable non-cytokine treated group. Genes 
analyzed included tyrosine hydroxylase (TH), dopamine β-hydroxylase (DBH), and phenylethanolamine N-
methyltransferase (PNMT). Changes in transcript were determined using RT-qPCR and changes in PNMT 
promoter activation were determined using luciferase assay. GC = Glucocorticoid; cAMP = Cyclic Adenosine 
Monophosphate. 
 
Cytokine 
Treatment 
Gene Basal Transcript GC- or cAMP-
Induced 
Transcript 
Promoter 
Activation 
   6h 24h Dex Fsk Ctl Dex 
IFN-α 
TH ↓ ↓  ↓ - - 
DBH     - - 
PNMT   ↓  ↓ ↓ 
IL-1β 
TH ↓    - - 
DBH     - - 
PNMT     - - 
IL-2 
TH ↓    - - 
DBH     - - 
PNMT     - - 
IL-6 
TH  ↓   - - 
DBH  ↑ ↑ ↑ - - 
PNMT   ↓    
IL-10 
TH     - - 
DBH     - - 
PNMT   ↑    
TNF-α 
TH ↓ ↓ ↓ ↓ - - 
DBH  ↓ ↓ ↓ - - 
PNMT   ↓  ↓ ↓ 
CCL2 
TH     - - 
DBH    ↑ - - 
PNMT     - - 
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